<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Fluid &amp; Electrolytes, DKA/HHS, Renal Disorders &mdash; Comprehensive Study Guide</title>
<style>
  :root {
    --pearl-bg: #e8f4fd;
    --pearl-border: #2196F3;
    --warning-bg: #fde8e8;
    --warning-border: #e53935;
    --memory-bg: #f3e8fd;
    --memory-border: #7B1FA2;
    --section-bg: #fafafa;
    --heading-color: #1a237e;
    --subheading-color: #283593;
    --text-color: #212121;
    --table-header: #1a237e;
    --table-alt: #f5f5f5;
    --link-color: #1565c0;
    --heavy-tag: #c62828;
    --slides-tag: #1565c0;
    --code-bg: #f5f5f5;
  }

  * { box-sizing: border-box; margin: 0; padding: 0; }

  body {
    font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
    font-size: 16px;
    line-height: 1.7;
    color: var(--text-color);
    background: #fff;
    margin: 0;
    padding: 0;
  }

  .page-layout {
    min-height: 100vh;
    padding-left: 260px;
  }

  /* Sidebar */
  .sidebar {
    width: 260px;
    background: #f5f7fa;
    border-right: 1px solid #c5cae9;
    padding: 1.5rem 1rem;
    position: fixed;
    top: 0;
    left: 0;
    height: 100vh;
    overflow-y: auto;
    z-index: 10;
  }

  .sidebar::-webkit-scrollbar { width: 5px; }
  .sidebar::-webkit-scrollbar-thumb { background: #c5cae9; border-radius: 3px; }

  /* Main content */
  .main-content {
    max-width: 960px;
    padding: 2rem 2.5rem 4rem;
    margin: 0 auto;
  }

  h1 {
    font-size: 2rem;
    color: var(--heading-color);
    border-bottom: 3px solid var(--heading-color);
    padding-bottom: 0.5rem;
    margin-bottom: 0.5rem;
  }

  h2 {
    font-size: 1.6rem;
    color: var(--heading-color);
    margin-top: 3rem;
    margin-bottom: 1rem;
    border-bottom: 2px solid #c5cae9;
    padding-bottom: 0.3rem;
  }

  h3 {
    font-size: 1.3rem;
    color: var(--subheading-color);
    margin-top: 2rem;
    margin-bottom: 0.75rem;
  }

  h4 {
    font-size: 1.1rem;
    color: #37474f;
    margin-top: 1.5rem;
    margin-bottom: 0.5rem;
  }

  p { margin-bottom: 1rem; }

  .subtitle {
    font-size: 1rem;
    color: #616161;
    margin-bottom: 2rem;
  }

  /* Source tags */
  .tag-slides {
    display: inline-block;
    font-size: 0.75rem;
    font-weight: 700;
    color: #fff;
    background: var(--slides-tag);
    padding: 1px 7px;
    border-radius: 3px;
    vertical-align: middle;
    margin-left: 6px;
  }
  .tag-heavy {
    display: inline-block;
    font-size: 0.75rem;
    font-weight: 700;
    color: #fff;
    background: var(--heavy-tag);
    padding: 1px 7px;
    border-radius: 3px;
    vertical-align: middle;
    margin-left: 6px;
  }

  /* Callout boxes */
  .callout {
    border-left: 4px solid;
    border-radius: 4px;
    padding: 1rem 1.25rem;
    margin: 1.25rem 0;
  }
  .callout-title {
    font-weight: 700;
    font-size: 0.95rem;
    margin-bottom: 0.4rem;
  }
  .pearl {
    background: var(--pearl-bg);
    border-color: var(--pearl-border);
  }
  .pearl .callout-title { color: var(--pearl-border); }
  .warning {
    background: var(--warning-bg);
    border-color: var(--warning-border);
  }
  .warning .callout-title { color: var(--warning-border); }
  .memory {
    background: var(--memory-bg);
    border-color: var(--memory-border);
  }
  .memory .callout-title { color: var(--memory-border); }

  /* Tables */
  table {
    width: 100%;
    border-collapse: collapse;
    margin: 1.25rem 0;
    font-size: 0.92rem;
  }
  th {
    background: var(--table-header);
    color: #fff;
    font-weight: 600;
    text-align: left;
    padding: 0.6rem 0.75rem;
  }
  td {
    padding: 0.5rem 0.75rem;
    border-bottom: 1px solid #e0e0e0;
    vertical-align: top;
  }
  tr:nth-child(even) td { background: var(--table-alt); }

  /* Lists */
  ul, ol { margin: 0.5rem 0 1rem 1.5rem; }
  li { margin-bottom: 0.3rem; }

  /* SVG containers */
  .diagram-container {
    margin: 1.5rem 0;
    text-align: center;
  }
  .diagram-container svg {
    max-width: 100%;
    height: auto;
  }

  /* Table of contents (sidebar) */
  .toc {
    background: transparent;
    border: none;
    border-radius: 0;
    padding: 0;
    margin: 0;
  }
  .toc h2 {
    margin-top: 0;
    border-bottom: 2px solid #c5cae9;
    font-size: 1rem;
    padding-bottom: 0.4rem;
    margin-bottom: 0.75rem;
  }
  .toc > ol { margin-left: 0; padding-left: 1.1rem; }
  .toc li {
    margin-bottom: 0.3rem;
    font-size: 0.85rem;
    line-height: 1.4;
  }
  .toc a {
    color: var(--link-color);
    text-decoration: none;
  }
  .toc a:hover { text-decoration: underline; color: var(--heading-color); }
  .toc .sub { margin-left: 0.5rem; padding-left: 0.75rem; font-size: 0.8rem; }
  .toc a.active {
    font-weight: 700;
    color: var(--heading-color);
  }

  /* Focus indicators */
  a:focus-visible {
    outline: 2px solid var(--link-color);
    outline-offset: 2px;
    border-radius: 2px;
  }
  button:focus-visible {
    outline: 2px solid var(--link-color);
    outline-offset: 2px;
  }
  *:focus-visible {
    outline: 2px solid var(--link-color);
    outline-offset: 2px;
  }

  /* Skip link */
  .skip-link {
    position: absolute;
    top: -40px;
    left: 0;
    background: var(--heading-color);
    color: white;
    padding: 8px 16px;
    text-decoration: none;
    z-index: 100;
    font-weight: 600;
    border-radius: 0 0 4px 0;
  }
  .skip-link:focus {
    top: 0;
  }

  /* Emphasis */
  strong { color: #1a237e; }
  em { font-style: italic; }

  /* Flowchart styling */
  .flow-box {
    display: inline-block;
    border: 2px solid #1a237e;
    border-radius: 6px;
    padding: 0.5rem 1rem;
    margin: 0.25rem;
    background: #e8eaf6;
    font-size: 0.9rem;
    font-weight: 600;
  }
  .flow-arrow {
    display: inline-block;
    font-size: 1.2rem;
    color: #1a237e;
    margin: 0 0.3rem;
    vertical-align: middle;
  }
  .flow-container {
    text-align: center;
    margin: 1.25rem 0;
    line-height: 2.5;
  }

  @media (max-width: 900px) {
    .page-layout { padding-left: 0; }
    .sidebar {
      width: 100%;
      height: auto;
      position: relative;
      border-right: none;
      border-bottom: 1px solid #c5cae9;
      padding: 1rem 1.5rem;
    }
    .main-content { padding: 1.5rem 1.25rem 3rem; }
  }

  @media print {
    .page-layout { display: block; }
    .sidebar { display: none; }
    .main-content { max-width: 100%; padding: 0; font-size: 11pt; }
    .callout { break-inside: avoid; }
    table { break-inside: avoid; }
    h2 { break-after: avoid; }
  }
</style>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>
<div class="page-layout">

<aside class="sidebar">
<nav class="toc" aria-label="Table of contents">
<h2>Contents</h2>
<ol>
  <li><a href="#s1">Diabetes Mellitus: Foundations</a>
    <ol class="sub">
      <li><a href="#s1a">Pathophysiology &amp; Classification</a></li>
      <li><a href="#s1b">Insulin Physiology &amp; Therapy</a></li>
      <li><a href="#s1c">Oral &amp; Non-Insulin Agents</a></li>
      <li><a href="#s1d">Glucose Monitoring &amp; Self-Management</a></li>
    </ol>
  </li>
  <li><a href="#s2">Acute Complications of Diabetes</a>
    <ol class="sub">
      <li><a href="#s2a">Hypoglycemia</a></li>
      <li><a href="#s2b">Diabetic Ketoacidosis (DKA)</a></li>
      <li><a href="#s2c">Hyperglycemic Hyperosmolar Syndrome (HHS)</a></li>
      <li><a href="#s2d">DKA vs. HHS: Side-by-Side</a></li>
    </ol>
  </li>
  <li><a href="#s3">Long-Term Complications of Diabetes</a></li>
  <li><a href="#s4">Kidney Disease Foundations</a>
    <ol class="sub">
      <li><a href="#s4a">Acute Kidney Injury (AKI)</a></li>
      <li><a href="#s4b">Chronic Kidney Disease &amp; ESKD</a></li>
      <li><a href="#s4c">Electrolyte Disturbances in Renal Failure</a></li>
    </ol>
  </li>
  <li><a href="#s5">Renal Replacement Therapy</a>
    <ol class="sub">
      <li><a href="#s5a">Hemodialysis</a></li>
      <li><a href="#s5b">Peritoneal Dialysis</a></li>
      <li><a href="#s5c">CRRT</a></li>
      <li><a href="#s5d">Hospitalized Dialysis Patient</a></li>
    </ol>
  </li>
  <li><a href="#s6">Kidney Surgery &amp; Transplantation</a>
    <ol class="sub">
      <li><a href="#s6a">Kidney Surgery</a></li>
      <li><a href="#s6b">Kidney Transplantation</a></li>
      <li><a href="#s6c">Immunosuppressants</a></li>
      <li><a href="#s6d">Post-Transplant Nursing</a></li>
    </ol>
  </li>
  <li><a href="#integration">Diabetes-to-Dialysis Continuum</a></li>
</ol>
</nav>
</aside>

<main id="main-content" class="main-content">

<h1>Fluid &amp; Electrolytes, DKA/HHS, and Renal Disorders</h1>
<p class="subtitle">Comprehensive Learning Document &mdash; Brunner Chapters 46 &amp; 48 | Lecture Slides | Practice Question Emphasis</p>

<!-- ============================================================ -->
<!-- SECTION 1: DIABETES FOUNDATIONS -->
<!-- ============================================================ -->
<h2 id="s1">1. Diabetes Mellitus: Foundations <span class="tag-slides">SLIDES</span></h2>

<h3 id="s1a">1.1 Pathophysiology &amp; Classification</h3>

<p>Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Approximately 34.1 million Americans have diabetes, and roughly one-third remain undiagnosed. Prevalence is increasing across all age groups, with minority populations and older adults disproportionately affected.</p>

<p>Understanding the <em>why</em> behind the classification matters because it determines everything downstream&mdash;which complications threaten the patient, which treatments work, and which emergencies to anticipate.</p>

<h4>Type 1 Diabetes</h4>
<p>Beta-cell destruction (autoimmune or idiopathic) leads to absolute insulin deficiency. Without insulin, glucose cannot enter cells, and the body turns to fat for fuel&mdash;a metabolic cascade that, when uncontrolled, produces ketoacidosis. Onset is typically acute, often presenting with the "three Ps" (polyuria, polydipsia, polyphagia) alongside sudden weight loss. Type 1 patients are insulin-dependent for life.</p>

<h4>Type 2 Diabetes</h4>
<p>A dual defect of insulin resistance and progressive beta-cell dysfunction accounts for approximately 95% of adult diabetes. The body produces insulin but not enough to overcome tissue resistance. Onset is gradual, often diagnosed incidentally through routine labs. DKA is uncommon in Type 2; instead, uncontrolled Type 2 progresses toward HHS&mdash;a slower, more insidious, and often deadlier emergency.</p>

<h4>Other Classifications</h4>
<ul>
  <li><strong>LADA</strong> (Latent Autoimmune Diabetes of Adults): autoimmune destruction presenting in adulthood, often misclassified as Type 2 initially</li>
  <li><strong>Gestational diabetes</strong>: insulin resistance driven by placental hormones, resolves postpartum but signals future Type 2 risk</li>
  <li><strong>Secondary diabetes</strong>: associated with other conditions (Cushing syndrome, pancreatitis, medications)</li>
</ul>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  COVID-19 and diabetes have a dangerous bidirectional relationship. Diabetic patients who contract COVID have significantly higher rates of intubation and death. The inflammatory cascade of severe COVID also appears to trigger new-onset diabetes in some patients.
</div>

<h4>Diagnostic Criteria</h4>
<table>
  <tr><th>Test</th><th>Diagnostic Threshold</th><th>Notes</th></tr>
  <tr><td>Fasting Plasma Glucose (FPG)</td><td>&ge; 126 mg/dL</td><td>Fasting &ge; 8 hours</td></tr>
  <tr><td>Random (Casual) Plasma Glucose</td><td>&ge; 200 mg/dL</td><td>With classic symptoms</td></tr>
  <tr><td>2-Hour OGTT</td><td>&ge; 200 mg/dL</td><td>Using 75g glucose load</td></tr>
  <tr><td>HgbA1C</td><td>&ge; 6.5%</td><td>Reflects 2&ndash;3 month average</td></tr>
</table>
<p>All results must be confirmed by repeat testing on a different day unless unequivocal hyperglycemia with acute metabolic decompensation is present.</p>

<h3 id="s1b">1.2 Insulin Physiology &amp; Therapy <span class="tag-slides">SLIDES</span></h3>

<p>Insulin is the master regulatory hormone of metabolism. When it works properly, it does far more than lower blood glucose&mdash;it orchestrates the storage and utilization of all three macronutrients:</p>
<ul>
  <li>Transports glucose into cells for energy</li>
  <li>Stimulates glycogen storage in liver and muscle</li>
  <li>Signals the liver to stop releasing stored glucose</li>
  <li>Promotes dietary fat storage in adipose tissue</li>
  <li>Accelerates amino acid transport into cells</li>
  <li>Inhibits breakdown of stored glucose, protein, and fat</li>
</ul>

<p>When insulin is absent (Type 1) or insufficient (Type 2), every one of these functions fails simultaneously. The body is swimming in glucose it cannot use, breaking down fat and protein in desperation, and generating toxic byproducts in the process.</p>

<h4>Insulin Categories &amp; Time Course</h4>
<table>
  <tr><th>Category</th><th>Examples</th><th>Onset</th><th>Peak</th><th>Duration</th><th>Key Points</th></tr>
  <tr><td><strong>Rapid-acting</strong></td><td>Lispro, Aspart, Glulisine</td><td>5&ndash;15 min</td><td>30 min&ndash;1 h</td><td>3&ndash;5 h</td><td>Give immediately before or with meals</td></tr>
  <tr><td><strong>Short-acting</strong></td><td>Regular (Humulin R)</td><td>30&ndash;60 min</td><td>2&ndash;3 h</td><td>4&ndash;6 h</td><td><strong>ONLY insulin approved for IV use.</strong> Give 15&ndash;30 min before meals</td></tr>
  <tr><td><strong>Intermediate</strong></td><td>NPH</td><td>1&ndash;1.5 h</td><td>4&ndash;12 h</td><td>Up to 24 h</td><td>Appears cloudy/milky. Roll gently, never shake</td></tr>
  <tr><td><strong>Long-acting</strong></td><td>Glargine, Detemir</td><td>3&ndash;6 h</td><td>No peak (continuous)</td><td>24 h</td><td>Cannot mix with other insulins (pH 4). "Peakless"</td></tr>
  <tr><td><strong>Inhaled</strong></td><td>Afrezza</td><td>&lt; 15 min</td><td>~50 min</td><td>2&ndash;3 h</td><td>Rapid-acting, pulmonary function testing required</td></tr>
</table>

<svg viewBox="0 0 740 420" style="max-width: 740px;" role="img" aria-label="Insulin action timeline graph showing four insulin types plotted over 24 hours. Rapid-acting (lispro, aspart) in red peaks sharply at 30-60 minutes and lasts 3-5 hours. Short-acting (regular) in orange peaks at 2-3 hours and lasts 4-6 hours. Intermediate (NPH) in blue peaks broadly at 4-12 hours and lasts up to 24 hours. Long-acting (glargine) in green shows a flat peakless line lasting 24 hours. Meal times for breakfast, lunch, and dinner are overlaid.">
    <defs>
        <linearGradient id="ins-grid" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#fafafa"/>
            <stop offset="100%" stop-color="#f5f5f5"/>
        </linearGradient>
    </defs>

    <!-- Title -->
    <text x="370" y="24" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">Insulin Action Profiles Over 24 Hours</text>

    <!-- Grid background -->
    <rect x="80" y="40" width="600" height="280" rx="4" fill="url(#ins-grid)" stroke="#e0e0e0" stroke-width="1"/>

    <!-- Y-axis -->
    <line x1="80" y1="40" x2="80" y2="320" stroke="#9e9e9e" stroke-width="1"/>
    <text x="40" y="180" text-anchor="middle" font-size="11" fill="#4a5568" font-weight="bold" transform="rotate(-90 40 180)">Insulin Activity</text>
    <text x="72" y="55" text-anchor="end" font-size="9" fill="#9e9e9e">High</text>
    <text x="72" y="185" text-anchor="end" font-size="9" fill="#9e9e9e">Med</text>
    <text x="72" y="318" text-anchor="end" font-size="9" fill="#9e9e9e">Low</text>

    <!-- X-axis -->
    <line x1="80" y1="320" x2="680" y2="320" stroke="#9e9e9e" stroke-width="1"/>
    <text x="370" y="345" text-anchor="middle" font-size="11" fill="#4a5568" font-weight="bold">Time (Hours)</text>

    <!-- X-axis labels (0-24 hours, 25px per hour) -->
    <text x="80" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">0</text>
    <text x="130" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">2</text>
    <text x="180" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">4</text>
    <text x="230" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">6</text>
    <text x="280" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">8</text>
    <text x="330" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">10</text>
    <text x="380" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">12</text>
    <text x="430" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">14</text>
    <text x="480" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">16</text>
    <text x="530" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">18</text>
    <text x="580" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">20</text>
    <text x="630" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">22</text>
    <text x="680" y="336" text-anchor="middle" font-size="9" fill="#9e9e9e">24</text>

    <!-- Vertical gridlines every 2 hours -->
    <line x1="130" y1="40" x2="130" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="180" y1="40" x2="180" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="230" y1="40" x2="230" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="280" y1="40" x2="280" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="330" y1="40" x2="330" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="380" y1="40" x2="380" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="430" y1="40" x2="430" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="480" y1="40" x2="480" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="530" y1="40" x2="530" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="580" y1="40" x2="580" y2="320" stroke="#eeeeee" stroke-width="0.5"/>
    <line x1="630" y1="40" x2="630" y2="320" stroke="#eeeeee" stroke-width="0.5"/>

    <!-- Meal time markers -->
    <rect x="80" y="40" width="5" height="280" fill="#d97706" opacity="0.15"/>
    <text x="83" y="52" font-size="8" fill="#d97706" font-weight="bold">B</text>
    <rect x="230" y="40" width="5" height="280" fill="#d97706" opacity="0.15"/>
    <text x="233" y="52" font-size="8" fill="#d97706" font-weight="bold">L</text>
    <rect x="405" y="40" width="5" height="280" fill="#d97706" opacity="0.15"/>
    <text x="408" y="52" font-size="8" fill="#d97706" font-weight="bold">D</text>

    <!-- Rapid-acting curve (Red) - onset 5-15 min, peak 30-60 min, duration 3-5 hr -->
    <path d="M 83,310 C 90,250 95,80 100,60 C 105,80 120,200 155,290 C 175,310 195,315 205,315"
          fill="none" stroke="#c62828" stroke-width="2.5" opacity="0.85"/>

    <!-- Short-acting curve (Orange) - onset 30-60 min, peak 2-3 hr, duration 4-6 hr -->
    <path d="M 88,312 C 100,290 115,200 130,120 C 145,90 160,100 175,140 C 200,200 230,280 280,310 C 290,315 300,315 305,315"
          fill="none" stroke="#d97706" stroke-width="2.5" opacity="0.85"/>

    <!-- Intermediate curve (Blue) - onset 1-1.5 hr, peak 4-12 hr, duration up to 24 hr -->
    <path d="M 93,312 C 110,300 130,270 180,170 C 230,110 280,100 330,110 C 380,120 430,160 480,220 C 530,270 580,300 630,310 C 650,313 670,315 680,315"
          fill="none" stroke="#1565c0" stroke-width="2.5" opacity="0.85"/>

    <!-- Long-acting line (Green) - onset 3-6 hr, no peak, duration 24 hr (flat) -->
    <path d="M 105,312 C 130,300 155,240 180,230 C 205,222 250,220 350,220 C 450,220 550,222 600,224 C 640,226 660,228 680,230"
          fill="none" stroke="#2e7d32" stroke-width="2.5" opacity="0.85" stroke-dasharray="8,4"/>

    <!-- Legend -->
    <rect x="80" y="360" width="600" height="55" rx="6" fill="white" stroke="#e0e0e0" stroke-width="1"/>

    <line x1="100" y1="378" x2="130" y2="378" stroke="#c62828" stroke-width="2.5"/>
    <text x="135" y="382" font-size="10" fill="#c62828" font-weight="bold">Rapid-acting</text>
    <text x="135" y="395" font-size="9" fill="#4a5568">Lispro, Aspart (5-15 min onset)</text>

    <line x1="275" y1="378" x2="305" y2="378" stroke="#d97706" stroke-width="2.5"/>
    <text x="310" y="382" font-size="10" fill="#d97706" font-weight="bold">Short-acting</text>
    <text x="310" y="395" font-size="9" fill="#4a5568">Regular (30-60 min, ONLY IV)</text>

    <line x1="450" y1="378" x2="480" y2="378" stroke="#1565c0" stroke-width="2.5"/>
    <text x="485" y="382" font-size="10" fill="#1565c0" font-weight="bold">Intermediate</text>
    <text x="485" y="395" font-size="9" fill="#4a5568">NPH (1-1.5h onset, cloudy)</text>

    <line x1="610" y1="378" x2="640" y2="378" stroke="#2e7d32" stroke-width="2.5" stroke-dasharray="8,4"/>
    <text x="645" y="382" font-size="10" fill="#2e7d32" font-weight="bold">Long-acting</text>
    <text x="645" y="395" font-size="9" fill="#4a5568">Glargine (peakless, 24h)</text>

    <!-- Meal legend -->
    <rect x="245" y="400" width="8" height="8" fill="#d97706" opacity="0.4"/>
    <text x="258" y="408" font-size="9" fill="#d97706">B = Breakfast | L = Lunch | D = Dinner</text>
</svg>

<div class="callout warning">
  <div class="callout-title">Safety Alert</div>
  Regular insulin is the ONLY insulin that can be given intravenously. In DKA, a continuous regular insulin drip is standard. Never give any other insulin type IV&mdash;the kinetics are unpredictable and dangerous.
</div>

<h4>Complications of Insulin Therapy</h4>
<p>Local allergic reactions, systemic allergic reactions, and insulin lipodystrophy (lumpy fatty deposits or atrophied areas at injection sites from repeated use of the same spot) are all possible. Site rotation prevents lipodystrophy, and return demonstration is the gold standard for verifying patient technique.</p>

<h4>Morning Hyperglycemia: Three Causes, Three Different Fixes</h4>
<p>When a patient wakes up with high blood glucose, the instinct is to increase insulin. But the cause matters enormously because the wrong adjustment can make things worse. The diagnostic move is checking blood glucose at bedtime, 3 AM, and upon waking.</p>

<table>
  <tr><th>Phenomenon</th><th>BG Pattern</th><th>Mechanism</th><th>Treatment</th></tr>
  <tr><td><strong>Insulin waning</strong></td><td>Progressive rise bedtime &rarr; morning</td><td>Evening insulin wearing off too soon</td><td>Increase evening dose or add bedtime insulin</td></tr>
  <tr><td><strong>Dawn phenomenon</strong></td><td>Normal until ~3 AM, then rises</td><td>Nocturnal growth hormone surge</td><td>Move NPH from dinnertime to bedtime</td></tr>
  <tr><td><strong>Somogyi effect</strong></td><td>Normal/elevated at bedtime &rarr; 3 AM hypoglycemia &rarr; rebound hyperglycemia</td><td>Counter-regulatory hormones respond to overnight low</td><td><em>Decrease</em> evening NPH or increase bedtime snack</td></tr>
</table>

<div class="callout memory">
  <div class="callout-title">Memory Anchor</div>
  <strong>Somogyi = Swing.</strong> Blood sugar swings low, then bounces high. The treatment is <em>less</em> insulin, not more&mdash;counterintuitive but critical. If you increase insulin in a Somogyi patient, you make the overnight hypoglycemia worse and the rebound even higher.
</div>

<h3 id="s1c">1.3 Oral &amp; Non-Insulin Agents <span class="tag-slides">SLIDES</span></h3>

<p>Oral agents are used in Type 2 diabetes when diet and exercise alone are insufficient. While hypoglycemia is a concern with <strong>sulfonylureas and secretagogues</strong>, most other classes (metformin, SGLT2 inhibitors, TZDs, GLP-1 agonists, DPP-4 inhibitors) carry low standalone hypoglycemia risk. Combination therapy is common because each class targets a different piece of the metabolic puzzle.</p>

<table>
  <tr><th>Class</th><th>Examples</th><th>Mechanism</th><th>Key Nursing Considerations</th></tr>
  <tr><td><strong>Biguanides</strong></td><td>Metformin</td><td>Inhibits hepatic glucose production</td><td>Risk of <strong>lactic acidosis</strong>. Stop 48h before/after contrast dye. Contraindicated in impaired renal/hepatic function. Monitor BUN/creatinine</td></tr>
  <tr><td><strong>Sulfonylureas</strong></td><td>Glimepiride, Glipizide, Glyburide</td><td>Stimulate pancreatic beta cells to secrete insulin</td><td>Risk of <strong>hypoglycemia</strong>. Contraindicated with sulfa allergy. Beta-blockers mask hypoglycemia symptoms</td></tr>
  <tr><td><strong>Alpha-glucosidase inhibitors</strong></td><td>Acarbose, Miglitol</td><td>Delay carbohydrate absorption in GI tract</td><td>Take with first bite of meal. Treat hypoglycemia with <strong>glucose</strong>, not sucrose (drug blocks sucrose absorption)</td></tr>
  <tr><td><strong>DPP-4 inhibitors</strong></td><td>Sitagliptin</td><td>Increase incretin levels &rarr; more insulin, less glucagon</td><td>Weight-neutral</td></tr>
  <tr><td><strong>GLP-1 agonists</strong></td><td>Dulaglutide, Liraglutide</td><td>Incretin mimetic &rarr; insulin release, slow gastric emptying</td><td>SQ injection. Weight loss benefit. Risk of pancreatitis</td></tr>
  <tr><td><strong>SGLT2 inhibitors</strong></td><td>Canagliflozin</td><td>Prevent renal glucose reabsorption &rarr; glycosuria</td><td>Risk of UTIs and genital infections. Weight loss</td></tr>
  <tr><td><strong>Thiazolidinediones</strong></td><td>Pioglitazone, Rosiglitazone</td><td>Sensitize peripheral tissue to insulin</td><td>Risk of edema, weight gain, liver dysfunction. Monitor LFTs</td></tr>
  <tr><td><strong>Non-sulfonylurea secretagogues</strong></td><td>Repaglinide, Nateglinide</td><td>Rapid, short-acting beta-cell stimulation</td><td>Take only if eating. Skip dose if meal skipped</td></tr>
</table>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; Metformin &amp; Contrast Dye</div>
  Metformin must be held 48 hours before AND after any procedure involving iodinated contrast dye. The combination can precipitate lactic acidosis, especially in patients with any degree of renal impairment. Always check renal function (BUN, creatinine) before restarting.
</div>

<h3 id="s1d">1.4 Glucose Monitoring &amp; Self-Management <span class="tag-slides">SLIDES</span></h3>

<p>Self-monitoring of blood glucose (SMBG) is the cornerstone of diabetes management. The ADA recommends maintaining an HgbA1C below 7%, which correlates with an estimated average glucose of roughly 154 mg/dL. The five pillars of diabetes management work together: nutritional therapy, exercise, glucose monitoring, pharmacologic therapy, and education.</p>

<h4>Nutritional Therapy</h4>
<p>Meal planning considers food preferences, lifestyle, and cultural background. General guidelines target carbohydrates at 50&ndash;60% of calories (emphasizing whole grains), fat below 30% (saturated fat below 10%), and cholesterol under 300 mg/day. The glycemic index matters: combining starches with protein or fat slows absorption, and whole fruits are preferred over juice because the fiber blunts the glucose spike.</p>

<h4>Exercise Considerations</h4>
<p>Exercise lowers blood glucose, aids weight loss, reduces cardiovascular risk, and manages stress. But it requires careful insulin adjustment. Moderate exercise can cause delayed hypoglycemia hours later, while intense exercise (weightlifting, sprinting) triggers adrenaline release, which paradoxically raises blood glucose through counter-regulatory hormone effects and may require <em>more</em> insulin. A 15g carbohydrate snack before and after moderate exercise helps prevent hypoglycemia.</p>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  When assessing patient readiness for diabetes self-management education, check readiness to learn <em>before</em> launching into teaching. A newly diagnosed patient who is overwhelmed, in pain, or grieving the diagnosis is not going to retain insulin injection technique. Prioritize "survival skills" first: recognizing hypo/hyperglycemia, when to call for help, and basic medication administration.
</div>

<!-- ============================================================ -->
<!-- SECTION 2: ACUTE COMPLICATIONS -->
<!-- ============================================================ -->
<h2 id="s2">2. Acute Complications of Diabetes <span class="tag-heavy">HEAVY IN SLIDES</span></h2>

<p>These three emergencies&mdash;hypoglycemia, DKA, and HHS&mdash;represent the most immediately life-threatening complications of diabetes. The lecture slides devoted more coverage to this section than any other, and practice questions test it from multiple angles. The ability to differentiate between them, initiate correct treatment, and understand the underlying physiology is non-negotiable.</p>

<svg viewBox="0 0 740 440" style="max-width: 740px;" role="img" aria-label="Hypoglycemia versus Hyperglycemia comparison. Left side in blue shows hypoglycemia below 70 mg/dL with symptoms of sweating, tremor, tachycardia, confusion, hunger; causes of too much insulin, exercise, missed meal; treatment is Rule of 15 with 15 grams carbs and recheck in 15 minutes. Right side in red shows hyperglycemia above 250 mg/dL with symptoms of polyuria, polydipsia, polyphagia, fatigue, blurred vision; causes of missed insulin, illness, stress, infection; treatment is insulin, fluids, identify cause.">
    <defs>
        <linearGradient id="hypo-bg" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#e3f2fd"/>
            <stop offset="100%" stop-color="#bbdefb"/>
        </linearGradient>
        <linearGradient id="hyper-bg" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#ffebee"/>
            <stop offset="100%" stop-color="#ffcdd2"/>
        </linearGradient>
    </defs>

    <!-- Title -->
    <text x="370" y="26" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">Hypoglycemia vs. Hyperglycemia</text>

    <!-- ===== LEFT: HYPOGLYCEMIA ===== -->
    <rect x="15" y="42" width="345" height="390" rx="10" fill="url(#hypo-bg)" stroke="#1565c0" stroke-width="2"/>
    <rect x="15" y="42" width="345" height="38" rx="10" fill="#1565c0"/>
    <rect x="15" y="70" width="345" height="10" fill="#1565c0"/>
    <text x="187" y="67" text-anchor="middle" font-size="15" font-weight="bold" fill="white">HYPOGLYCEMIA</text>

    <!-- Down arrow icon -->
    <circle cx="187" cy="110" r="22" fill="white" stroke="#1565c0" stroke-width="2"/>
    <text x="187" y="118" text-anchor="middle" font-size="22" fill="#1565c0" font-weight="bold">&darr;</text>
    <text x="187" y="148" text-anchor="middle" font-size="13" font-weight="bold" fill="#c62828">&lt; 70 mg/dL</text>
    <text x="187" y="164" text-anchor="middle" font-size="10" fill="#1565c0">(Clinically significant &lt;54)</text>

    <!-- Symptoms -->
    <text x="35" y="186" font-size="12" fill="#0d47a1" font-weight="bold">Symptoms:</text>
    <text x="35" y="204" font-size="10" fill="#1a237e">&bull; Sweating (diaphoresis), pallor</text>
    <text x="35" y="218" font-size="10" fill="#1a237e">&bull; Tremor, shakiness</text>
    <text x="35" y="232" font-size="10" fill="#1a237e">&bull; Tachycardia, palpitations</text>
    <text x="35" y="246" font-size="10" fill="#1a237e">&bull; Confusion, irritability</text>
    <text x="35" y="260" font-size="10" fill="#1a237e">&bull; Hunger (intense)</text>
    <text x="35" y="274" font-size="10" fill="#1a237e">&bull; Seizures, LOC (severe)</text>

    <!-- Causes -->
    <text x="35" y="298" font-size="12" fill="#0d47a1" font-weight="bold">Causes:</text>
    <text x="35" y="314" font-size="10" fill="#1a237e">&bull; Too much insulin/oral agent</text>
    <text x="35" y="328" font-size="10" fill="#1a237e">&bull; Excessive exercise</text>
    <text x="35" y="342" font-size="10" fill="#1a237e">&bull; Missed or delayed meal</text>

    <!-- Treatment -->
    <rect x="30" y="355" width="315" height="68" rx="6" fill="white" stroke="#1565c0" stroke-width="1.5" opacity="0.9"/>
    <text x="187" y="375" text-anchor="middle" font-size="12" fill="#1565c0" font-weight="bold">Treatment: RULE OF 15</text>
    <text x="187" y="393" text-anchor="middle" font-size="11" fill="#0d47a1">15g fast-acting carbs (juice, glucose tabs)</text>
    <text x="187" y="409" text-anchor="middle" font-size="11" fill="#0d47a1">Recheck BG in 15 min &rarr; repeat if &lt;70</text>
    <text x="187" y="422" text-anchor="middle" font-size="10" fill="#c62828" font-weight="bold">If unconscious: Glucagon IM or D50 IV</text>

    <!-- ===== RIGHT: HYPERGLYCEMIA ===== -->
    <rect x="380" y="42" width="345" height="390" rx="10" fill="url(#hyper-bg)" stroke="#c62828" stroke-width="2"/>
    <rect x="380" y="42" width="345" height="38" rx="10" fill="#c62828"/>
    <rect x="380" y="70" width="345" height="10" fill="#c62828"/>
    <text x="552" y="67" text-anchor="middle" font-size="15" font-weight="bold" fill="white">HYPERGLYCEMIA</text>

    <!-- Up arrow icon -->
    <circle cx="552" cy="110" r="22" fill="white" stroke="#c62828" stroke-width="2"/>
    <text x="552" y="118" text-anchor="middle" font-size="22" fill="#c62828" font-weight="bold">&uarr;</text>
    <text x="552" y="148" text-anchor="middle" font-size="13" font-weight="bold" fill="#c62828">&gt; 250 mg/dL</text>
    <text x="552" y="164" text-anchor="middle" font-size="10" fill="#b71c1c">(Progresses to DKA or HHS)</text>

    <!-- Symptoms -->
    <text x="400" y="186" font-size="12" fill="#b71c1c" font-weight="bold">Symptoms (3 Ps + more):</text>
    <text x="400" y="204" font-size="10" fill="#b71c1c">&bull; Polyuria (frequent urination)</text>
    <text x="400" y="218" font-size="10" fill="#b71c1c">&bull; Polydipsia (extreme thirst)</text>
    <text x="400" y="232" font-size="10" fill="#b71c1c">&bull; Polyphagia (extreme hunger)</text>
    <text x="400" y="246" font-size="10" fill="#b71c1c">&bull; Fatigue, weakness</text>
    <text x="400" y="260" font-size="10" fill="#b71c1c">&bull; Blurred vision</text>
    <text x="400" y="274" font-size="10" fill="#b71c1c">&bull; Slow wound healing</text>

    <!-- Causes -->
    <text x="400" y="298" font-size="12" fill="#b71c1c" font-weight="bold">Causes:</text>
    <text x="400" y="314" font-size="10" fill="#b71c1c">&bull; Missed or insufficient insulin</text>
    <text x="400" y="328" font-size="10" fill="#b71c1c">&bull; Illness, infection, stress</text>
    <text x="400" y="342" font-size="10" fill="#b71c1c">&bull; Excessive carbohydrate intake</text>

    <!-- Treatment -->
    <rect x="395" y="355" width="315" height="68" rx="6" fill="white" stroke="#c62828" stroke-width="1.5" opacity="0.9"/>
    <text x="552" y="375" text-anchor="middle" font-size="12" fill="#c62828" font-weight="bold">Treatment:</text>
    <text x="552" y="393" text-anchor="middle" font-size="11" fill="#b71c1c">Insulin (per sliding scale or correction)</text>
    <text x="552" y="409" text-anchor="middle" font-size="11" fill="#b71c1c">IV fluids, identify and treat cause</text>
    <text x="552" y="422" text-anchor="middle" font-size="10" fill="#c62828" font-weight="bold">If DKA/HHS developing &rarr; EMERGENCY</text>
</svg>

<h3 id="s2a">2.1 Hypoglycemia <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<p>Hypoglycemia occurs when blood glucose drops below 70 mg/dL, with clinically significant hypoglycemia defined at below 54 mg/dL. The three most common causes are too much insulin or oral hypoglycemic agent, too much physical activity, and not enough food. The clinical presentation follows a predictable neurologic deterioration as glucose drops lower.</p>

<h4>Severity Classification</h4>
<table>
  <tr><th>Severity</th><th>BG Range</th><th>Symptoms</th><th>Mechanism</th></tr>
  <tr><td><strong>Mild</strong></td><td>54&ndash;70 mg/dL</td><td>Sweating, tremor, tachycardia, palpitations, nervousness, hunger</td><td>Adrenergic (sympathetic nervous system activation)</td></tr>
  <tr><td><strong>Moderate</strong></td><td>Below 54 mg/dL</td><td>Inability to concentrate, headache, confusion, memory lapses, slurred speech, drowsiness, numbness of lips/tongue</td><td>CNS glucose deprivation (neuroglycopenia)</td></tr>
  <tr><td><strong>Severe</strong></td><td>Well below 54 mg/dL</td><td>Disorientation, seizures, loss of consciousness, death</td><td>Severe cerebral glucose deprivation</td></tr>
</table>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; Hypoglycemic Unawareness</div>
  Patients with autonomic neuropathy (common in long-standing diabetes) lose the adrenergic warning signs&mdash;no sweating, no tremor, no tachycardia. They go straight from "feeling fine" to confused or unconscious. This is called <strong>hypoglycemic unawareness</strong>, and these patients need tighter monitoring and education about frequent glucose checks.
</div>

<h4>Management of Hypoglycemia</h4>

<p><strong>Conscious patient (Rule of 15):</strong> Give 15&ndash;20 grams of fast-acting concentrated carbohydrate: 3&ndash;4 glucose tablets, or 4&ndash;6 ounces of juice or regular soda (never diet). Recheck blood glucose in 15 minutes. If still below 70 mg/dL or symptoms persist beyond 10&ndash;15 minutes, repeat treatment. Once glucose normalizes, provide a snack of protein plus complex carbohydrate unless a meal is planned within 30&ndash;60 minutes.</p>

<p><strong>Unconscious or unable to swallow (BG &lt; 54 mg/dL):</strong></p>
<ul>
  <li><strong>In hospital:</strong> IV push 25&ndash;50 mL of D50W (50% dextrose)</li>
  <li><strong>Outside hospital:</strong> SQ or IM glucagon 1 mg. Position on side (glucagon causes nausea; risk of aspiration when consciousness returns)</li>
</ul>

<div class="callout memory">
  <div class="callout-title">Memory Anchor</div>
  <strong>Conscious = Carbs. Unconscious = D50 (hospital) or Glucagon (community).</strong> Never try to put juice into the mouth of an unconscious patient&mdash;aspiration risk is immediate and lethal.
</div>

<h3 id="s2b">2.2 Diabetic Ketoacidosis (DKA) <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<p>DKA is the result of absent or grossly inadequate insulin, leading to simultaneous metabolic catastrophe: hyperglycemia, dehydration, ketosis, and metabolic acidosis. It is most common in Type 1 diabetes but can occur in poorly managed Type 2 during severe physiologic stress. The three main precipitating events are missed insulin doses, illness or infection, and undiagnosed/untreated diabetes.</p>

<h4>The DKA Cascade</h4>

<div class="diagram-container">
<svg viewBox="0 0 800 520" xmlns="http://www.w3.org/2000/svg" width="800" height="520" role="img" aria-label="DKA Pathophysiology Cascade: absent insulin leads to hyperglycemia and ketone production, causing osmotic diuresis, severe dehydration, and metabolic acidosis">
  <defs>
    <marker id="ah1" markerWidth="10" markerHeight="7" refX="10" refY="3.5" orient="auto"><polygon points="0 0, 10 3.5, 0 7" fill="#424242"/></marker>
    <marker id="ah1g" markerWidth="10" markerHeight="7" refX="10" refY="3.5" orient="auto"><polygon points="0 0, 10 3.5, 0 7" fill="#2e7d32"/></marker>
  </defs>
  <rect width="800" height="520" fill="#fafafa" rx="8"/>
  <text x="400" y="30" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">DKA Pathophysiology Cascade</text>
  <rect x="280" y="45" width="240" height="36" rx="6" fill="#c62828" stroke="#b71c1c" stroke-width="1.5"/>
  <text x="400" y="68" text-anchor="middle" font-size="13" fill="#fff" font-weight="bold">ABSENT / INADEQUATE INSULIN</text>
  <line x1="400" y1="81" x2="400" y2="100" stroke="#424242" stroke-width="2" marker-end="url(#ah1)"/>
  <rect x="80" y="105" width="260" height="34" rx="6" fill="#1565c0" stroke="#0d47a1" stroke-width="1.5"/>
  <text x="210" y="127" text-anchor="middle" font-size="12" fill="#fff" font-weight="600">Glucose can&#x27;t enter cells + Gluconeogenesis &#x2191;</text>
  <rect x="460" y="105" width="260" height="34" rx="6" fill="#1565c0" stroke="#0d47a1" stroke-width="1.5"/>
  <text x="590" y="127" text-anchor="middle" font-size="12" fill="#fff" font-weight="600">Lipolysis &#x2192; Free Fatty Acids &#x2191;</text>
  <line x1="330" y1="81" x2="210" y2="105" stroke="#424242" stroke-width="1.5"/>
  <line x1="470" y1="81" x2="590" y2="105" stroke="#424242" stroke-width="1.5"/>
  <rect x="110" y="160" width="200" height="30" rx="5" fill="#e8eaf6" stroke="#3949ab" stroke-width="1.5"/>
  <text x="210" y="180" text-anchor="middle" font-size="12" fill="#1a237e" font-weight="600">HYPERGLYCEMIA (250&#x2013;800+)</text>
  <line x1="210" y1="139" x2="210" y2="160" stroke="#424242" stroke-width="1.5" marker-end="url(#ah1)"/>
  <rect x="480" y="160" width="220" height="30" rx="5" fill="#e8eaf6" stroke="#3949ab" stroke-width="1.5"/>
  <text x="590" y="180" text-anchor="middle" font-size="12" fill="#1a237e" font-weight="600">Liver converts FFA &#x2192; KETONES</text>
  <line x1="590" y1="139" x2="590" y2="160" stroke="#424242" stroke-width="1.5" marker-end="url(#ah1)"/>
  <rect x="90" y="210" width="240" height="34" rx="5" fill="#e8eaf6" stroke="#3949ab" stroke-width="1.5"/>
  <text x="210" y="225" text-anchor="middle" font-size="11" fill="#1a237e">Kidneys excrete excess glucose</text>
  <text x="210" y="239" text-anchor="middle" font-size="11" fill="#1a237e" font-weight="bold">OSMOTIC DIURESIS</text>
  <line x1="210" y1="190" x2="210" y2="210" stroke="#424242" stroke-width="1.5" marker-end="url(#ah1)"/>
  <rect x="470" y="210" width="240" height="34" rx="5" fill="#fde8e8" stroke="#c62828" stroke-width="1.5"/>
  <text x="590" y="225" text-anchor="middle" font-size="11" fill="#c62828">Ketone accumulation</text>
  <text x="590" y="239" text-anchor="middle" font-size="11" fill="#c62828" font-weight="bold">METABOLIC ACIDOSIS</text>
  <line x1="590" y1="190" x2="590" y2="210" stroke="#424242" stroke-width="1.5" marker-end="url(#ah1)"/>
  <rect x="70" y="265" width="280" height="40" rx="5" fill="#fff3e0" stroke="#e65100" stroke-width="1.5"/>
  <text x="210" y="282" text-anchor="middle" font-size="11" fill="#e65100">Loss of 6&#x2013;7 L water + 400&#x2013;500 mEq Na+/K+ in 24h</text>
  <text x="210" y="298" text-anchor="middle" font-size="12" fill="#e65100" font-weight="bold">SEVERE DEHYDRATION</text>
  <line x1="210" y1="244" x2="210" y2="265" stroke="#424242" stroke-width="1.5" marker-end="url(#ah1)"/>
  <rect x="460" y="265" width="260" height="40" rx="5" fill="#fff3e0" stroke="#e65100" stroke-width="1.5"/>
  <text x="590" y="282" text-anchor="middle" font-size="11" fill="#e65100">pH 6.8&#x2013;7.3 | Bicarb 0&#x2013;15 mEq/L</text>
  <text x="590" y="298" text-anchor="middle" font-size="12" fill="#e65100" font-weight="bold">Kussmaul respirations + Fruity breath</text>
  <line x1="590" y1="244" x2="590" y2="265" stroke="#424242" stroke-width="1.5" marker-end="url(#ah1)"/>
  <line x1="210" y1="305" x2="400" y2="340" stroke="#424242" stroke-width="1.5"/>
  <line x1="590" y1="305" x2="400" y2="340" stroke="#424242" stroke-width="1.5"/>
  <rect x="200" y="340" width="400" height="50" rx="6" fill="#c62828" stroke="#b71c1c" stroke-width="2"/>
  <text x="400" y="360" text-anchor="middle" font-size="12" fill="#fff">Hypotension | Weak pulse | Tachycardia | N/V | Altered mental status</text>
  <text x="400" y="380" text-anchor="middle" font-size="14" fill="#fff" font-weight="bold">COMA &amp; DEATH if untreated</text>
  <rect x="170" y="420" width="460" height="80" rx="8" fill="#e8f5e9" stroke="#2e7d32" stroke-width="2"/>
  <text x="400" y="442" text-anchor="middle" font-size="13" fill="#2e7d32" font-weight="bold">TREATMENT PRIORITIES</text>
  <text x="400" y="462" text-anchor="middle" font-size="12" fill="#1b5e20">1. Rehydration (NS 500&#x2013;1000 mL/hr) &#x2192; 2. IV Regular Insulin</text>
  <text x="400" y="480" text-anchor="middle" font-size="12" fill="#1b5e20">3. Electrolyte replacement (K+ is #1 concern) &#x2192; 4. Reverse acidosis</text>
  <text x="400" y="498" text-anchor="middle" font-size="11" fill="#2e7d32">When BG reaches 250&#x2013;300: add dextrose to IV fluids</text>
  <line x1="400" y1="390" x2="400" y2="420" stroke="#2e7d32" stroke-width="2" marker-end="url(#ah1g)"/>
</svg>
</div>

<h4>DKA Assessment Findings</h4>
<table>
  <tr><th>Parameter</th><th>Finding</th></tr>
  <tr><td>Blood glucose</td><td>250&ndash;800+ mg/dL (can exceed 1000)</td></tr>
  <tr><td>Arterial pH</td><td>6.8&ndash;7.3 (normal 7.35&ndash;7.45)</td></tr>
  <tr><td>Serum bicarbonate</td><td>0&ndash;15 mEq/L (normal 22&ndash;26)</td></tr>
  <tr><td>PCO2</td><td>10&ndash;30 mmHg (respiratory compensation)</td></tr>
  <tr><td>Anion gap</td><td>Elevated (&gt;12 mEq/L)</td></tr>
  <tr><td>Serum/urine ketones</td><td>Present</td></tr>
  <tr><td>BUN, creatinine, Hct</td><td>Elevated (hemoconcentration from dehydration)</td></tr>
  <tr><td>Potassium</td><td>Variable&mdash;may appear normal or high initially despite total body depletion</td></tr>
</table>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; The Potassium Trap in DKA</div>
  Serum potassium may look normal or even elevated on admission because acidosis drives K+ out of cells into the blood. But total body potassium is <em>depleted</em> from osmotic diuresis. As you correct the acidosis with insulin and fluids, K+ shifts back into cells and serum levels plummet. If you are not aggressively replacing potassium, the patient can develop fatal hypokalemia and cardiac arrest. <strong>K+ must be maintained &ge; 4 mEq/L. Replace even if levels appear normal. Withhold replacement ONLY if hyperkalemic or not urinating.</strong>
</div>

<h4>DKA Treatment Protocol</h4>
<ol>
  <li><strong>Rehydration FIRST</strong> (before correcting hyperglycemia with insulin):
    <ul>
      <li>0.9% NS at 500&ndash;1000 mL/hr for first 2&ndash;4 hours</li>
      <li>Then 0.45% NS at 200&ndash;500 mL/hr for several more hours</li>
      <li>Total: 6&ndash;10 liters may be needed</li>
      <li>When BG reaches 250&ndash;300 mg/dL, switch to D5W to prevent precipitous drop</li>
    </ul>
  </li>
  <li><strong>IV Regular Insulin</strong>:
    <ul>
      <li>Continuous drip at ~5 units/hr</li>
      <li>Flush insulin through entire IV tubing first (insulin adheres to plastic)</li>
      <li>Monitor BG hourly (POCT); when at target &times; 4 consecutive hours, move to q2h</li>
      <li><strong>Do NOT stop insulin drip until SQ insulin has been started</strong></li>
    </ul>
  </li>
  <li><strong>Electrolyte Replacement</strong>:
    <ul>
      <li>K+ replacement: up to 40 mEq/hr may be needed. Add 20 mEq/L to IVF when K+ &lt; 4</li>
      <li>ECG monitoring q2&ndash;4h initially for first 8 hours</li>
      <li>Monitor Na+, K+, Cl-, Ca, Mg, Phos, BUN, creatinine q6h</li>
    </ul>
  </li>
  <li><strong>Reverse Acidosis</strong>:
    <ul>
      <li>Insulin itself reverses acidosis (stops ketone production)</li>
      <li>Bicarbonate infusion generally <strong>AVOIDED</strong>&mdash;it precipitates further K+ drops</li>
      <li>BG often corrects before acidosis; insulin drip may continue 12&ndash;24h until bicarb &ge;15&ndash;18 mEq/L</li>
    </ul>
  </li>
</ol>

<p><strong>Monitoring priorities:</strong> BG, renal function, urine output, ECG, electrolytes, VS, lung sounds (fluid overload risk). Use caution in patients with HF or renal failure&mdash;the aggressive fluid resuscitation needed for DKA can tip them into pulmonary edema.</p>

<h4>Anion Gap <span class="tag-slides">SLIDES</span></h4>
<p>The anion gap helps confirm metabolic acidosis in DKA. Normal anion gap is <strong>8&ndash;12 mEq/L</strong> (without K+) or <strong>12&ndash;16 mEq/L</strong> (with K+). In DKA, ketoacid accumulation widens the gap significantly. A closing anion gap during treatment signals that acidosis is resolving.</p>

<h4>Pseudohyponatremia in DKA <span class="tag-slides">SLIDES</span></h4>
<p>Hyperglycemia creates hyperosmolality, which pulls water from the intracellular space into the extracellular space, diluting serum sodium. The sodium level on the lab report is falsely low. Use the correction formula:</p>
<p><strong>Corrected Na+ = Measured Na+ + [1.6 &times; (Glucose - 100) / 100]</strong></p>

<h4>Sick Day Rules <span class="tag-slides">SLIDES</span></h4>
<ul>
  <li><strong>NEVER eliminate insulin doses</strong> when ill, even if not eating&mdash;illness and stress hormones raise blood glucose</li>
  <li>Test BG more frequently (every 3&ndash;4 hours)</li>
  <li>Test urine for ketones if BG &gt; 300 mg/dL</li>
  <li>Take supplemental fluids every hour if possible</li>
  <li>Call provider if: BG &gt; 300 mg/dL &times; 2 readings, positive ketones, unable to keep fluids down, illness lasting &gt; 1&ndash;2 days</li>
</ul>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  Practice questions test sick day rules from multiple angles because patients consistently get this wrong in real life. The most common fatal mistake is skipping insulin because "I'm not eating." Stress hormones from illness, infection, or surgery raise blood glucose even without food intake. The insulin is still needed&mdash;it just may need dose adjustment.
</div>

<h3 id="s2c">2.3 Hyperglycemic Hyperosmolar Syndrome (HHS) <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<p>HHS is the metabolic emergency of Type 2 diabetes. Unlike DKA, the body produces <em>enough</em> insulin to prevent fat breakdown and ketosis, but <em>not enough</em> to prevent hyperglycemia. The result is an insidious, progressive osmotic diuresis that plays out over days to weeks, culminating in profound dehydration, dangerous hyperosmolality, and neurologic deterioration.</p>

<p>HHS typically occurs in older adults with Type 2 diabetes (sometimes undiagnosed), often triggered by a physiologic stressor: stroke, infection, or medications that worsen hyperglycemia (thiazide diuretics). Because there is no ketoacidosis and no GI symptoms, the patient does not feel acutely ill&mdash;they tolerate the polyuria and polydipsia until neurologic changes finally bring them to medical attention. By then, dehydration is severe.</p>

<h4>HHS Clinical Features</h4>
<ul>
  <li>Blood glucose: 600&ndash;1200+ mg/dL</li>
  <li>Serum osmolality: &gt; 320 mOsm/L (vs. normal 275&ndash;295)</li>
  <li>Arterial pH: <strong>normal</strong> (no acidosis)</li>
  <li>Ketones: absent or minimal</li>
  <li>Profound dehydration, hypotension, tachycardia</li>
  <li>Variable neurologic signs from cerebral dehydration: confusion, lethargy, seizures, hallucinations, coma</li>
  <li><strong>HIGH MORTALITY RATE: 5&ndash;16%</strong> (compared to &lt;1% for DKA)</li>
</ul>

<h4>HHS Treatment</h4>
<p><strong>Fluid and electrolyte replacement is the FIRST priority</strong>&mdash;even before insulin. The extreme dehydration is more dangerous than the hyperglycemia. Normal saline or half-normal saline (depending on sodium level and volume status) is given aggressively with central venous or hemodynamic pressure monitoring to guide volume. Insulin plays a less important role than in DKA because there is no acidosis to reverse. After recovery, many patients can control their diabetes with medical nutrition therapy alone or with oral agents.</p>

<div class="callout memory">
  <div class="callout-title">Memory Anchor</div>
  <strong>DKA = Dry, Ketotic, Acidotic.</strong> Young Type 1 patient, rapid onset, fruity breath, Kussmaul breathing.<br/>
  <strong>HHS = High sugar, Hyperosmolar, Sneaky.</strong> Older Type 2 patient, slow onset, no ketones, altered mental status is the hallmark. Higher mortality because patients present later.
</div>

<h3 id="s2d">2.4 DKA vs. HHS: Side-by-Side <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<table>
  <tr><th>Feature</th><th>DKA</th><th>HHS</th></tr>
  <tr><td><strong>Most common in</strong></td><td>Type 1 (can occur in Type 2)</td><td>Type 2, especially older adults</td></tr>
  <tr><td><strong>Precipitating event</strong></td><td>Omitted insulin, infection, illness</td><td>Physiologic stress, medications (thiazides), dialysis</td></tr>
  <tr><td><strong>Onset</strong></td><td>Rapid (&lt; 24 hours)</td><td>Slower (days to weeks)</td></tr>
  <tr><td><strong>Blood glucose</strong></td><td>Usually &gt; 250 mg/dL</td><td>Usually &gt; 600 mg/dL</td></tr>
  <tr><td><strong>Arterial pH</strong></td><td>&lt; 7.3</td><td>Normal</td></tr>
  <tr><td><strong>Ketones</strong></td><td>Present (blood &amp; urine)</td><td>Absent or minimal</td></tr>
  <tr><td><strong>Serum osmolality</strong></td><td>275&ndash;320 mOsm/L</td><td>&gt; 320 mOsm/L</td></tr>
  <tr><td><strong>Bicarb</strong></td><td>&lt; 15 mEq/L</td><td>Normal</td></tr>
  <tr><td><strong>Respirations</strong></td><td>Kussmaul (deep, rapid)</td><td>Normal or shallow</td></tr>
  <tr><td><strong>Breath</strong></td><td>Fruity/acetone odor</td><td>No fruity odor</td></tr>
  <tr><td><strong>Hallmark presentation</strong></td><td>GI symptoms (N/V, abdominal pain)</td><td>Altered mental status</td></tr>
  <tr><td><strong>Treatment priority</strong></td><td>Fluids + Insulin + K+ replacement</td><td>Fluids FIRST, then insulin (less central role)</td></tr>
  <tr><td><strong>Mortality rate</strong></td><td><strong>&lt; 1%</strong></td><td><strong>5&ndash;16%</strong></td></tr>
</table>

<svg viewBox="0 0 740 580" style="max-width: 740px;" role="img" aria-label="DKA versus HHS side-by-side visual comparison. Left panel shows DKA in Type 1 diabetes with rapid onset under 24 hours, blood glucose 250-800, pH below 7.3 with acidosis, ketones present, Kussmaul respirations, fruity breath, GI symptoms, and less than 1% mortality. Right panel shows HHS in Type 2 diabetes with slow onset over days to weeks, blood glucose 600-1200 plus, normal pH, ketones absent, normal respirations, altered mental status, and 5-16% mortality. Common features in center include severe dehydration and electrolyte imbalances.">
    <defs>
        <linearGradient id="dka-bg" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#ffebee"/>
            <stop offset="100%" stop-color="#ffcdd2"/>
        </linearGradient>
        <linearGradient id="hhs-bg" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#e8eaf6"/>
            <stop offset="100%" stop-color="#c5cae9"/>
        </linearGradient>
    </defs>

    <!-- Title -->
    <text x="370" y="26" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">DKA vs. HHS &mdash; Visual Comparison</text>

    <!-- ===== LEFT: DKA ===== -->
    <rect x="15" y="45" width="335" height="475" rx="10" fill="url(#dka-bg)" stroke="#c62828" stroke-width="2"/>
    <rect x="15" y="45" width="335" height="38" rx="10" fill="#c62828"/>
    <rect x="15" y="73" width="335" height="10" fill="#c62828"/>
    <text x="182" y="70" text-anchor="middle" font-size="15" font-weight="bold" fill="white">DKA (Diabetic Ketoacidosis)</text>

    <text x="182" y="106" text-anchor="middle" font-size="12" fill="#c62828" font-weight="bold">Primarily Type 1</text>

    <!-- DKA features -->
    <rect x="30" y="118" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#e57373" stroke-width="1"/>
    <text x="45" y="137" font-size="11" fill="#b71c1c"><tspan font-weight="bold">Onset:</tspan> Rapid (&lt; 24 hours)</text>

    <rect x="30" y="152" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#e57373" stroke-width="1"/>
    <text x="45" y="171" font-size="11" fill="#b71c1c"><tspan font-weight="bold">BG:</tspan> 250&ndash;800 mg/dL</text>

    <rect x="30" y="186" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#e57373" stroke-width="1"/>
    <text x="45" y="205" font-size="11" fill="#b71c1c"><tspan font-weight="bold">pH:</tspan> &lt; 7.3 (ACIDOSIS)</text>
    <text x="315" y="205" text-anchor="end" font-size="10" fill="#c62828" font-weight="bold">&darr;&darr;&darr;</text>

    <rect x="30" y="220" width="305" height="28" rx="4" fill="#ffcdd2" stroke="#c62828" stroke-width="1.5"/>
    <text x="45" y="239" font-size="11" fill="#b71c1c" font-weight="bold">Ketones: PRESENT (blood &amp; urine)</text>

    <rect x="30" y="254" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#e57373" stroke-width="1"/>
    <text x="45" y="273" font-size="11" fill="#b71c1c"><tspan font-weight="bold">Respirations:</tspan> Kussmaul (deep, rapid)</text>

    <rect x="30" y="288" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#e57373" stroke-width="1"/>
    <text x="45" y="307" font-size="11" fill="#b71c1c"><tspan font-weight="bold">Breath:</tspan> Fruity/acetone odor</text>

    <rect x="30" y="322" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#e57373" stroke-width="1"/>
    <text x="45" y="341" font-size="11" fill="#b71c1c"><tspan font-weight="bold">Hallmark:</tspan> GI symptoms (N/V, abd pain)</text>

    <!-- Mortality -->
    <rect x="80" y="362" width="180" height="35" rx="8" fill="#2e7d32" stroke="#1b5e20" stroke-width="1.5"/>
    <text x="170" y="384" text-anchor="middle" font-size="14" font-weight="bold" fill="white">Mortality: &lt; 1%</text>

    <!-- Treatment -->
    <text x="182" y="418" text-anchor="middle" font-size="12" fill="#c62828" font-weight="bold">Treatment Priority:</text>
    <text x="182" y="438" text-anchor="middle" font-size="12" fill="#b71c1c">1. Fluids (NS)</text>
    <text x="182" y="456" text-anchor="middle" font-size="12" fill="#b71c1c">2. Insulin drip (Regular)</text>
    <text x="182" y="474" text-anchor="middle" font-size="12" fill="#b71c1c">3. K+ replacement</text>
    <text x="182" y="495" text-anchor="middle" font-size="10" fill="#c62828" font-style="italic">(Check K+ BEFORE insulin&mdash;</text>
    <text x="182" y="509" text-anchor="middle" font-size="10" fill="#c62828" font-style="italic">insulin drives K+ into cells)</text>

    <!-- ===== RIGHT: HHS ===== -->
    <rect x="390" y="45" width="335" height="475" rx="10" fill="url(#hhs-bg)" stroke="#283593" stroke-width="2"/>
    <rect x="390" y="45" width="335" height="38" rx="10" fill="#283593"/>
    <rect x="390" y="73" width="335" height="10" fill="#283593"/>
    <text x="557" y="70" text-anchor="middle" font-size="15" font-weight="bold" fill="white">HHS (Hyperosmolar Syndrome)</text>

    <text x="557" y="106" text-anchor="middle" font-size="12" fill="#283593" font-weight="bold">Primarily Type 2 (Older Adults)</text>

    <!-- HHS features -->
    <rect x="405" y="118" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#7986cb" stroke-width="1"/>
    <text x="420" y="137" font-size="11" fill="#1a237e"><tspan font-weight="bold">Onset:</tspan> Slow (days to weeks)</text>

    <rect x="405" y="152" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#7986cb" stroke-width="1"/>
    <text x="420" y="171" font-size="11" fill="#1a237e"><tspan font-weight="bold">BG:</tspan> 600&ndash;1200+ mg/dL</text>
    <text x="690" y="171" text-anchor="end" font-size="10" fill="#c62828" font-weight="bold">&uarr;&uarr;&uarr;</text>

    <rect x="405" y="186" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#7986cb" stroke-width="1"/>
    <text x="420" y="205" font-size="11" fill="#1a237e"><tspan font-weight="bold">pH:</tspan> Normal (no acidosis)</text>

    <rect x="405" y="220" width="305" height="28" rx="4" fill="#c5cae9" stroke="#283593" stroke-width="1.5"/>
    <text x="420" y="239" font-size="11" fill="#1a237e" font-weight="bold">Ketones: ABSENT or minimal</text>

    <rect x="405" y="254" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#7986cb" stroke-width="1"/>
    <text x="420" y="273" font-size="11" fill="#1a237e"><tspan font-weight="bold">Respirations:</tspan> Normal or shallow</text>

    <rect x="405" y="288" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#7986cb" stroke-width="1"/>
    <text x="420" y="307" font-size="11" fill="#1a237e"><tspan font-weight="bold">Breath:</tspan> No fruity odor</text>

    <rect x="405" y="322" width="305" height="28" rx="4" fill="white" opacity="0.8" stroke="#7986cb" stroke-width="1"/>
    <text x="420" y="341" font-size="11" fill="#1a237e"><tspan font-weight="bold">Hallmark:</tspan> Altered mental status</text>

    <!-- Mortality -->
    <rect x="455" y="362" width="180" height="35" rx="8" fill="#c62828" stroke="#b71c1c" stroke-width="1.5"/>
    <text x="545" y="384" text-anchor="middle" font-size="14" font-weight="bold" fill="white">Mortality: 5&ndash;16%</text>

    <!-- Treatment -->
    <text x="557" y="418" text-anchor="middle" font-size="12" fill="#283593" font-weight="bold">Treatment Priority:</text>
    <text x="557" y="438" text-anchor="middle" font-size="12" fill="#1a237e">1. Fluids FIRST (massive deficit)</text>
    <text x="557" y="456" text-anchor="middle" font-size="12" fill="#1a237e">2. Then insulin (less central role)</text>
    <text x="557" y="474" text-anchor="middle" font-size="12" fill="#1a237e">3. Electrolyte monitoring</text>
    <text x="557" y="495" text-anchor="middle" font-size="10" fill="#283593" font-style="italic">(Fluid deficit can be 6-9 liters&mdash;</text>
    <text x="557" y="509" text-anchor="middle" font-size="10" fill="#283593" font-style="italic">rehydration is the priority)</text>

    <!-- ===== SHARED FEATURES (bottom center) ===== -->
    <rect x="220" y="530" width="300" height="42" rx="8" fill="#fff3e0" stroke="#d97706" stroke-width="2"/>
    <text x="370" y="549" text-anchor="middle" font-size="11" font-weight="bold" fill="#e65100">Both Share:</text>
    <text x="370" y="565" text-anchor="middle" font-size="10" fill="#bf360c">Severe dehydration &bull; Electrolyte imbalances &bull; Risk of death</text>
</svg>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  The fundamental question is: <strong>Why is DKA mortality so much lower than HHS?</strong> Two reasons: (1) DKA presents early because the GI symptoms are impossible to ignore, so patients get to the hospital sooner. (2) HHS patients are typically older with more comorbidities, and the insidious onset means they present with profound dehydration that is harder to reverse. The takeaway: speed of recognition determines survival in both conditions.
</div>

<!-- ============================================================ -->
<!-- SECTION 3: LONG-TERM COMPLICATIONS -->
<!-- ============================================================ -->
<h2 id="s3">3. Long-Term Complications of Diabetes <span class="tag-slides">SLIDES</span></h2>

<p>Chronic hyperglycemia damages blood vessels through two main pathways: macrovascular disease (accelerated atherosclerosis) and microvascular disease (damage to the smallest vessels). The longer diabetes is poorly controlled, the more severe these complications become. This is why the ADA A1C target of &lt; 7% exists&mdash;it is the threshold below which complication risk drops significantly.</p>

<h3>Macrovascular Complications</h3>
<p>Accelerated atherosclerosis affects the coronary arteries (CAD, MI), cerebral vessels (stroke), and peripheral arteries (peripheral vascular disease, claudication). Cardiovascular disease is the leading cause of death in diabetic patients. Risk reduction centers on tight glycemic control, blood pressure management, lipid management, smoking cessation, and antiplatelet therapy.</p>

<h3>Microvascular Complications</h3>

<h4>Diabetic Retinopathy</h4>
<p>Retinal damage progresses through three stages: nonproliferative (background), preproliferative, and proliferative. Microaneurysms and hemorrhages in the retina lead to progressive vision loss. Annual dilated eye exams are essential for early detection. Laser photocoagulation can slow progression.</p>

<h4>Diabetic Nephropathy</h4>
<p>The earliest detectable sign is microalbuminuria (&gt; 30 mg/24h on two consecutive tests). ACE inhibitors are first-line treatment because they slow progression independent of blood pressure effects. Uncontrolled nephropathy progresses to ESKD&mdash;creating the direct link between diabetes and the kidney failure discussed in the second half of this document.</p>

<h3>Neuropathic Complications</h3>

<h4>Peripheral Neuropathy</h4>
<p>The progression is characteristic: paresthesias and burning sensations &rarr; numbness &rarr; unsteady gait &rarr; Charcot joints (structural destruction from repeated undetected trauma). Monofilament testing is used to assess for loss of protective sensation. The earliest symptom patients notice is tingling in the feet.</p>

<h4>Autonomic Neuropathy</h4>
<p>Damage to autonomic nerves produces a constellation of seemingly unrelated symptoms: fixed tachycardia, orthostatic hypotension, gastroparesis (delayed gastric emptying&mdash;which makes glucose control unpredictable), neurogenic bladder, erectile dysfunction, and hypoglycemic unawareness.</p>

<h4>Diabetic Foot Care <span class="tag-slides">SLIDES</span></h4>
<p>The foot ulceration cascade demonstrates why neuropathy is so dangerous: minor injury or skin fissure &rarr; not detected because of absent sensation &rarr; progresses to infection &rarr; may lead to amputation. Patient education is critical:</p>
<ul>
  <li>Inspect feet daily (use mirror for soles)</li>
  <li>Never walk barefoot</li>
  <li>No heating pads or hot water bottles on feet (cannot feel burns)</li>
  <li>Wear properly fitting shoes</li>
  <li>Trim nails straight across</li>
  <li>Report any cuts, blisters, or color changes immediately</li>
</ul>

<!-- ============================================================ -->
<!-- SECTION 4: KIDNEY DISEASE FOUNDATIONS -->
<!-- ============================================================ -->
<h2 id="s4">4. Kidney Disease Foundations <span class="tag-heavy">HEAVY IN SLIDES</span></h2>

<p>The kidneys are the body's master regulators of fluid, electrolytes, acid-base balance, blood pressure, and red blood cell production. When they fail, every body system is affected. The two most common causes of kidney failure in the United States are diabetes mellitus and hypertension&mdash;directly linking the first half of this document to the second.</p>

<p>The critical distinction to internalize: <strong>AKI is reversible</strong> (if caught early and the cause is addressed). <strong>CKD/ESKD is progressive and irreversible.</strong></p>

<svg viewBox="0 0 720 560" style="max-width: 720px;" role="img" aria-label="Kidney nephron diagram showing glomerulus with afferent and efferent arterioles where GFR occurs, Bowman's capsule collecting filtrate, proximal tubule reabsorbing 65% of sodium water and glucose, Loop of Henle with descending limb permeable to water and ascending limb pumping out sodium, distal tubule fine-tuning sodium potassium and hydrogen, and collecting duct where ADH controls final water reabsorption. Diuretic action sites labeled: loop diuretics at ascending Loop of Henle, thiazides at distal tubule, K-sparing at collecting duct.">
    <defs>
        <marker id="neph-arrow" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="6" markerHeight="6" orient="auto-start-reverse">
            <path d="M 0 0 L 10 5 L 0 10 Z" fill="#4a5568"/>
        </marker>
        <marker id="neph-arrow-red" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="6" markerHeight="6" orient="auto-start-reverse">
            <path d="M 0 0 L 10 5 L 0 10 Z" fill="#c62828"/>
        </marker>
        <marker id="neph-arrow-blue" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="6" markerHeight="6" orient="auto-start-reverse">
            <path d="M 0 0 L 10 5 L 0 10 Z" fill="#1565c0"/>
        </marker>
    </defs>

    <!-- Title -->
    <text x="360" y="24" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">The Nephron &mdash; Functional Unit of the Kidney</text>

    <!-- ===== GLOMERULUS (top left) ===== -->
    <!-- Afferent arteriole -->
    <path d="M 50,120 C 80,120 100,110 130,100" fill="none" stroke="#c62828" stroke-width="3"/>
    <text x="40" y="115" font-size="10" fill="#c62828" font-weight="bold">Afferent</text>
    <text x="40" y="127" font-size="10" fill="#c62828">arteriole</text>
    <text x="40" y="142" font-size="9" fill="#c62828" font-style="italic">(blood IN)</text>

    <!-- Glomerulus cluster -->
    <circle cx="175" cy="95" r="40" fill="#ffebee" stroke="#c62828" stroke-width="2"/>
    <!-- Capillary loops -->
    <path d="M 155,80 Q 165,70 175,80 Q 185,90 175,100 Q 165,90 155,80" fill="none" stroke="#c62828" stroke-width="1.5"/>
    <path d="M 170,75 Q 180,65 190,75 Q 200,85 190,95 Q 180,85 170,75" fill="none" stroke="#c62828" stroke-width="1.5"/>
    <path d="M 160,90 Q 170,80 180,90 Q 190,100 180,110 Q 170,100 160,90" fill="none" stroke="#c62828" stroke-width="1.5"/>
    <text x="175" y="98" text-anchor="middle" font-size="10" font-weight="bold" fill="#c62828">GFR</text>

    <!-- Efferent arteriole -->
    <path d="M 200,75 C 220,65 240,75 240,90" fill="none" stroke="#1565c0" stroke-width="3"/>
    <text x="245" y="70" font-size="10" fill="#1565c0" font-weight="bold">Efferent</text>
    <text x="245" y="82" font-size="10" fill="#1565c0">(blood OUT)</text>

    <!-- Bowman's capsule -->
    <path d="M 130,60 Q 120,95 135,130 Q 175,155 215,130 Q 230,95 215,60 Q 175,40 130,60"
          fill="none" stroke="#7B1FA2" stroke-width="2" stroke-dasharray="6,3"/>
    <text x="175" y="50" text-anchor="middle" font-size="10" font-weight="bold" fill="#7B1FA2">Bowman's Capsule</text>

    <!-- GFR annotation -->
    <rect x="10" y="55" width="95" height="42" rx="4" fill="#fff3e0" stroke="#d97706" stroke-width="1"/>
    <text x="57" y="72" text-anchor="middle" font-size="9" fill="#e65100" font-weight="bold">GFR occurs here</text>
    <text x="57" y="86" text-anchor="middle" font-size="9" fill="#e65100">Normal: 90-120</text>
    <text x="57" y="96" text-anchor="middle" font-size="9" fill="#e65100">mL/min</text>

    <!-- Diabetes annotation -->
    <rect x="290" y="60" width="130" height="35" rx="4" fill="#ffcdd2" stroke="#c62828" stroke-width="1"/>
    <text x="355" y="76" text-anchor="middle" font-size="9" fill="#c62828" font-weight="bold">Diabetes damages</text>
    <text x="355" y="89" text-anchor="middle" font-size="9" fill="#c62828">glomerulus &rarr; proteinuria</text>
    <line x1="290" y1="80" x2="220" y2="90" stroke="#c62828" stroke-width="1" stroke-dasharray="3,3"/>

    <!-- ===== PROXIMAL TUBULE ===== -->
    <path d="M 175,135 C 175,160 200,180 250,190 C 300,200 350,200 380,195"
          fill="none" stroke="#2e7d32" stroke-width="4"/>
    <text x="280" y="175" text-anchor="middle" font-size="11" font-weight="bold" fill="#2e7d32">Proximal Tubule</text>
    <!-- Reabsorption arrows -->
    <text x="280" y="220" text-anchor="middle" font-size="10" fill="#1b5e20">Reabsorbs 65%: Na+, H&#8322;O, glucose, amino acids</text>
    <path d="M 260,195 L 260,210" stroke="#2e7d32" stroke-width="1" stroke-dasharray="2,2"/>

    <!-- ===== LOOP OF HENLE ===== -->
    <!-- Descending limb -->
    <path d="M 380,195 C 385,220 385,280 380,340 C 375,380 360,410 340,430"
          fill="none" stroke="#1565c0" stroke-width="4"/>
    <text x="410" y="280" font-size="10" fill="#1565c0" font-weight="bold">Descending</text>
    <text x="410" y="294" font-size="10" fill="#1565c0">H&#8322;O OUT</text>
    <text x="410" y="308" font-size="9" fill="#1565c0">(permeable</text>
    <text x="410" y="320" font-size="9" fill="#1565c0">to water)</text>

    <!-- Hairpin turn -->
    <path d="M 340,430 C 320,445 300,445 280,430"
          fill="none" stroke="#7B1FA2" stroke-width="4"/>

    <!-- Ascending limb -->
    <path d="M 280,430 C 260,410 255,380 260,340 C 265,280 270,220 280,195"
          fill="none" stroke="#d97706" stroke-width="4"/>
    <text x="215" y="310" text-anchor="end" font-size="10" fill="#d97706" font-weight="bold">Ascending</text>
    <text x="215" y="324" text-anchor="end" font-size="10" fill="#d97706">Na+ OUT</text>
    <text x="215" y="338" text-anchor="end" font-size="9" fill="#d97706">(impermeable</text>
    <text x="215" y="350" text-anchor="end" font-size="9" fill="#d97706">to water)</text>

    <text x="310" y="460" text-anchor="middle" font-size="11" font-weight="bold" fill="#7B1FA2">Loop of Henle</text>

    <!-- Loop diuretic action site -->
    <rect x="105" y="378" width="112" height="40" rx="6" fill="#ffcdd2" stroke="#c62828" stroke-width="2"/>
    <text x="161" y="395" text-anchor="middle" font-size="10" font-weight="bold" fill="#c62828">Loop Diuretics</text>
    <text x="161" y="410" text-anchor="middle" font-size="9" fill="#b71c1c">(furosemide)</text>
    <line x1="217" y1="395" x2="255" y2="380" stroke="#c62828" stroke-width="1.5" stroke-dasharray="4,3" marker-end="url(#neph-arrow-red)"/>

    <!-- ===== DISTAL TUBULE ===== -->
    <path d="M 280,195 C 280,180 310,170 350,170 C 400,170 440,175 470,190"
          fill="none" stroke="#7B1FA2" stroke-width="4"/>
    <text x="420" y="158" font-size="11" font-weight="bold" fill="#7B1FA2">Distal Tubule</text>
    <text x="420" y="172" font-size="10" fill="#6a1b9a">Fine-tunes Na+, K+, H+</text>

    <!-- Thiazide action site -->
    <rect x="470" y="135" width="112" height="40" rx="6" fill="#ffcdd2" stroke="#c62828" stroke-width="2"/>
    <text x="526" y="152" text-anchor="middle" font-size="10" font-weight="bold" fill="#c62828">Thiazides</text>
    <text x="526" y="167" text-anchor="middle" font-size="9" fill="#b71c1c">(HCTZ)</text>
    <line x1="470" y1="160" x2="450" y2="175" stroke="#c62828" stroke-width="1.5" stroke-dasharray="4,3" marker-end="url(#neph-arrow-red)"/>

    <!-- ===== COLLECTING DUCT ===== -->
    <path d="M 470,190 C 490,210 500,250 505,300 C 510,350 510,400 510,450 C 510,480 510,500 510,520"
          fill="none" stroke="#283593" stroke-width="4"/>
    <text x="545" y="370" font-size="11" font-weight="bold" fill="#283593">Collecting</text>
    <text x="545" y="384" font-size="11" font-weight="bold" fill="#283593">Duct</text>
    <text x="545" y="402" font-size="10" fill="#1a237e">ADH acts here</text>
    <text x="545" y="416" font-size="10" fill="#1a237e">&rarr; H&#8322;O reabsorbed</text>

    <!-- K-sparing diuretic action site -->
    <rect x="590" y="430" width="120" height="40" rx="6" fill="#ffcdd2" stroke="#c62828" stroke-width="2"/>
    <text x="650" y="447" text-anchor="middle" font-size="10" font-weight="bold" fill="#c62828">K+-Sparing</text>
    <text x="650" y="462" text-anchor="middle" font-size="9" fill="#b71c1c">(spironolactone)</text>
    <line x1="590" y1="450" x2="520" y2="440" stroke="#c62828" stroke-width="1.5" stroke-dasharray="4,3" marker-end="url(#neph-arrow-red)"/>

    <!-- Urine output -->
    <text x="510" y="545" text-anchor="middle" font-size="11" font-weight="bold" fill="#283593">&darr; To Renal Pelvis</text>
    <text x="510" y="558" text-anchor="middle" font-size="10" fill="#283593">(Urine)</text>

    <!-- Flow direction arrow along tubule -->
    <text x="200" y="200" font-size="9" fill="#4a5568" font-style="italic">filtrate flow &rarr;</text>

    <!-- Legend -->
    <rect x="15" y="485" width="180" height="70" rx="6" fill="white" stroke="#e0e0e0" stroke-width="1"/>
    <text x="25" y="502" font-size="10" fill="#4a5568" font-weight="bold">Legend:</text>
    <rect x="25" y="508" width="10" height="10" rx="2" fill="#c62828"/>
    <text x="40" y="518" font-size="9" fill="#4a5568">Arterial blood / Diuretic sites</text>
    <rect x="25" y="524" width="10" height="10" rx="2" fill="#2e7d32"/>
    <text x="40" y="534" font-size="9" fill="#4a5568">Proximal tubule (major reabsorption)</text>
    <rect x="25" y="540" width="10" height="10" rx="2" fill="#283593"/>
    <text x="40" y="550" font-size="9" fill="#4a5568">Collecting duct (ADH-dependent)</text>
</svg>

<h3 id="s4a">4.1 Acute Kidney Injury (AKI) <span class="tag-slides">SLIDES</span></h3>

<p>AKI is a sudden, potentially reversible decrease in kidney function characterized by rising BUN and creatinine and, usually, oliguria (urine output &lt; 400 mL/day). The RIFLE classification grades severity: Risk &rarr; Injury &rarr; Failure &rarr; Loss &rarr; ESKD.</p>

<h4>Three Categories of AKI</h4>
<table>
  <tr><th>Category</th><th>Mechanism</th><th>Common Causes</th><th>Diagnostic Clue</th></tr>
  <tr><td><strong>Prerenal</strong></td><td>Decreased blood flow to kidneys (hypoperfusion)</td><td>Hypovolemia, hemorrhage, heart failure, sepsis, burns, dehydration</td><td>BUN:Creatinine ratio &gt; 20:1</td></tr>
  <tr><td><strong>Intrarenal (Intrinsic)</strong></td><td>Direct damage to kidney tissue</td><td>ATN from prolonged ischemia, nephrotoxic drugs (aminoglycosides, contrast dye, NSAIDs), rhabdomyolysis (myoglobin), glomerulonephritis</td><td>Renal tubular casts in urine</td></tr>
  <tr><td><strong>Postrenal</strong></td><td>Obstruction of urine outflow</td><td>BPH, kidney stones, tumors, blood clots</td><td>Hydronephrosis on imaging; relief of obstruction restores function</td></tr>
</table>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  Practice questions test whether you understand the <em>mechanism</em>, not just the label. Burns cause prerenal AKI because massive fluid loss creates hypoperfusion. Aminoglycosides cause intrarenal AKI because they are directly toxic to tubular cells. Understanding the "why" helps you predict, prevent, and prioritize.
</div>

<h4>Four Phases of AKI</h4>

<div class="diagram-container">
<svg viewBox="0 0 800 200" xmlns="http://www.w3.org/2000/svg" width="800" height="200" role="img" aria-label="Four phases of Acute Kidney Injury: Initiation, Oliguria, Diuresis, and Recovery with key features of each phase">
  <rect width="800" height="200" fill="#fafafa" rx="6"/>
  <!-- Phase 1 -->
  <rect x="20" y="30" width="170" height="140" rx="8" fill="#e3f2fd" stroke="#1565c0" stroke-width="2"/>
  <text x="105" y="55" text-anchor="middle" font-size="13" font-weight="bold" fill="#1565c0">1. Initiation</text>
  <text x="105" y="78" text-anchor="middle" font-size="10" fill="#333">Begins with insult</text>
  <text x="105" y="93" text-anchor="middle" font-size="10" fill="#333">Ends when oliguria</text>
  <text x="105" y="108" text-anchor="middle" font-size="10" fill="#333">develops</text>
  <text x="105" y="130" text-anchor="middle" font-size="10" fill="#1565c0" font-weight="600">Hours to days</text>
  <text x="105" y="155" text-anchor="middle" font-size="9" fill="#666">Prevention is possible</text>
  <text x="105" y="165" text-anchor="middle" font-size="9" fill="#666">at this stage</text>

  <!-- Arrow -->
  <polygon points="197,100 210,90 210,110" fill="#424242"/>

  <!-- Phase 2 -->
  <rect x="215" y="30" width="170" height="140" rx="8" fill="#fce4ec" stroke="#c62828" stroke-width="2"/>
  <text x="300" y="55" text-anchor="middle" font-size="13" font-weight="bold" fill="#c62828">2. Oliguria</text>
  <text x="300" y="78" text-anchor="middle" font-size="10" fill="#333">UO &lt; 400 mL/day</text>
  <text x="300" y="93" text-anchor="middle" font-size="10" fill="#333">BUN/Cr rise</text>
  <text x="300" y="108" text-anchor="middle" font-size="10" fill="#333">Hyperkalemia</text>
  <text x="300" y="123" text-anchor="middle" font-size="10" fill="#333">Metabolic acidosis</text>
  <text x="300" y="145" text-anchor="middle" font-size="10" fill="#c62828" font-weight="600">10-14 days</text>
  <text x="300" y="162" text-anchor="middle" font-size="9" fill="#c62828">Longer = worse prognosis</text>

  <!-- Arrow -->
  <polygon points="392,100 405,90 405,110" fill="#424242"/>

  <!-- Phase 3 -->
  <rect x="410" y="30" width="170" height="140" rx="8" fill="#fff3e0" stroke="#e65100" stroke-width="2"/>
  <text x="495" y="55" text-anchor="middle" font-size="13" font-weight="bold" fill="#e65100">3. Diuresis</text>
  <text x="495" y="78" text-anchor="middle" font-size="10" fill="#333">UO increases</text>
  <text x="495" y="93" text-anchor="middle" font-size="10" fill="#333">(1-4.5 L/day)</text>
  <text x="495" y="108" text-anchor="middle" font-size="10" fill="#333">BUN may still rise</text>
  <text x="495" y="128" text-anchor="middle" font-size="10" fill="#e65100" font-weight="600">Risk: DEHYDRATION</text>
  <text x="495" y="145" text-anchor="middle" font-size="10" fill="#e65100">Hypokalemia</text>
  <text x="495" y="162" text-anchor="middle" font-size="9" fill="#666">Counterintuitive!</text>

  <!-- Arrow -->
  <polygon points="587,100 600,90 600,110" fill="#424242"/>

  <!-- Phase 4 -->
  <rect x="605" y="30" width="170" height="140" rx="8" fill="#e8f5e9" stroke="#2e7d32" stroke-width="2"/>
  <text x="690" y="55" text-anchor="middle" font-size="13" font-weight="bold" fill="#2e7d32">4. Recovery</text>
  <text x="690" y="78" text-anchor="middle" font-size="10" fill="#333">Gradual improvement</text>
  <text x="690" y="93" text-anchor="middle" font-size="10" fill="#333">in renal function</text>
  <text x="690" y="115" text-anchor="middle" font-size="10" fill="#2e7d32" font-weight="600">3-12 months</text>
  <text x="690" y="140" text-anchor="middle" font-size="10" fill="#333">May have permanent</text>
  <text x="690" y="155" text-anchor="middle" font-size="10" fill="#333">decrease in GFR</text>
  <text x="690" y="168" text-anchor="middle" font-size="9" fill="#666">Some progress to CKD</text>
</svg>
</div>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; The Diuresis Trap</div>
  The diuresis phase is counterintuitive and heavily tested on exams. The kidneys are recovering and beginning to produce urine again&mdash;but they cannot yet concentrate it properly. Output can reach 4.5 liters per day. The danger is now <strong>dehydration and electrolyte loss</strong>, the exact opposite of the oliguric phase. Patients need aggressive fluid and electrolyte replacement during diuresis. Watch for hypokalemia and hyponatremia.
</div>

<h4>AKI Prevention</h4>
<p>Many cases of AKI are iatrogenic&mdash;caused or worsened by medical treatment&mdash;and therefore preventable:</p>
<ul>
  <li>Pre-procedure IV hydration (NS) for patients receiving contrast dye</li>
  <li>Hold nephrotoxic medications before and after contrast</li>
  <li>Monitor drug levels for aminoglycosides and vancomycin</li>
  <li>N-acetylcysteine (Mucomyst) may be prescribed prophylactically before contrast</li>
  <li>Maintain adequate hydration in any patient receiving nephrotoxic drugs</li>
  <li>Avoid NSAIDs in patients with any degree of renal impairment</li>
</ul>

<h3 id="s4b">4.2 Chronic Kidney Disease &amp; ESKD <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<p>CKD is a progressive, irreversible deterioration of kidney function. As nephrons are destroyed, the remaining nephrons hypertrophy to compensate&mdash;but eventually, compensation fails and the accumulation of metabolic waste products (azotemia) produces systemic toxicity affecting every organ system.</p>

<h4>CKD Stages</h4>
<table>
  <tr><th>Stage</th><th>GFR (mL/min/1.73m&sup2;)</th><th>Description</th><th>Clinical Significance</th></tr>
  <tr><td>1</td><td>&gt; 90</td><td>Kidney damage, normal GFR</td><td>Focus on slowing progression</td></tr>
  <tr><td>2</td><td>60&ndash;89</td><td>Mild decrease</td><td>Monitor, manage comorbidities</td></tr>
  <tr><td>3</td><td>30&ndash;59</td><td>Moderate decrease</td><td>Complications begin (anemia, bone disease)</td></tr>
  <tr><td>4</td><td>15&ndash;29</td><td>Severe decrease</td><td>Prepare for RRT, vascular access planning</td></tr>
  <tr><td>5</td><td>&lt; 15 (or dialysis)</td><td>ESKD / Kidney failure</td><td>Dialysis or transplant required</td></tr>
</table>

<h4>Causes of CKD</h4>
<p>Diabetes mellitus and hypertension together account for the majority of CKD cases. Other causes include chronic glomerulonephritis, pyelonephritis, urinary tract obstruction, polycystic kidney disease, vascular disorders, and nephrotoxic medications.</p>

<h4>ESKD Pathophysiology &mdash; A Systemic Disease <span class="tag-heavy">HEAVY IN SLIDES</span></h4>
<p>When GFR drops critically, the body can no longer maintain homeostasis. Every system fails in a predictable pattern:</p>

<table>
  <tr><th>System</th><th>Manifestations</th><th>Mechanism</th></tr>
  <tr><td><strong>Fluid/Electrolyte</strong></td><td>Edema, HTN, heart failure</td><td>Na+ and water retention; inability to concentrate or dilute urine</td></tr>
  <tr><td><strong>Potassium</strong></td><td>Hyperkalemia &rarr; cardiac arrest</td><td>Decreased excretion, acidosis, catabolism</td></tr>
  <tr><td><strong>Acid-Base</strong></td><td>Metabolic acidosis</td><td>Cannot excrete H+ or regenerate bicarbonate</td></tr>
  <tr><td><strong>Hematologic</strong></td><td>Normochromic normocytic anemia, bleeding</td><td>Decreased EPO, shortened RBC lifespan, impaired platelet function</td></tr>
  <tr><td><strong>Cardiovascular</strong></td><td>HTN, HF, pericarditis, atherosclerosis</td><td>Volume overload, uremic toxins, RAAS dysfunction</td></tr>
  <tr><td><strong>Neurologic</strong></td><td>Lethargy, confusion, seizures, restless legs, peripheral neuropathy</td><td>Uremic toxin accumulation</td></tr>
  <tr><td><strong>GI</strong></td><td>Anorexia, N/V, hiccups, uremic fetor, stomatitis</td><td>Uremic toxins irritate GI mucosa</td></tr>
  <tr><td><strong>Musculoskeletal</strong></td><td>Renal osteodystrophy, pathologic fractures</td><td>Phosphate retention &rarr; calcium depletion &rarr; secondary hyperparathyroidism</td></tr>
  <tr><td><strong>Skin</strong></td><td>Pruritus, uremic frost, ecchymoses, yellowish-gray pallor</td><td>Urea and calcium-phosphate crystals deposited in skin</td></tr>
  <tr><td><strong>Endocrine</strong></td><td>Infertility, sexual dysfunction</td><td>Hormonal disruption from uremia</td></tr>
</table>

<div class="callout memory">
  <div class="callout-title">Memory Anchor &mdash; Renal Osteodystrophy Cascade</div>
  <strong>Phosphorus UP &rarr; Calcium DOWN &rarr; Vitamin D DOWN &rarr; PTH UP &rarr; Bones WEAKEN.</strong> Failed kidneys can't excrete phosphorus, so it accumulates. High phosphorus binds calcium (dropping serum calcium). The kidneys also can't convert vitamin D to its active form (calcitriol), so calcium absorption from the gut drops further. The parathyroid glands respond by secreting more PTH, which leaches calcium from bones. The result is brittle, fracture-prone bones.
</div>

<h4>Anemia Management in CKD/ESKD</h4>
<p>The kidneys produce erythropoietin (EPO), which stimulates red blood cell production. In kidney failure, EPO production plummets. Treatment includes epoetin alfa or darbepoetin injections, with target hemoglobin of 10&ndash;11.5 g/dL (higher targets increase vascular thrombosis risk). IV iron supplementation is usually needed concurrently, along with folic acid. Monitor for hypertension and vascular access thrombosis as side effects of EPO therapy.</p>

<h4>ESKD Nursing Assessment <span class="tag-slides">SLIDES</span></h4>
<ul>
  <li>Fluid status: daily weights, I&amp;O, edema, lung sounds, JVD</li>
  <li>Nutritional status: weight trends, albumin, protein intake</li>
  <li>Electrolyte balance: K+, Na+, Ca, Phos, Mg</li>
  <li>Activity tolerance and fatigue</li>
  <li>Self-esteem and coping</li>
  <li>Potential complications: hyperkalemia, pericarditis, infection</li>
</ul>

<h3 id="s4c">4.3 Electrolyte Disturbances in Renal Failure</h3>

<h4>Hyperkalemia &mdash; The Most Dangerous Electrolyte Emergency <span class="tag-heavy">HEAVY IN SLIDES</span></h4>

<p>Hyperkalemia is the electrolyte disturbance most likely to kill your patient. The kidneys normally excrete 80% of the body's potassium; when they fail, K+ accumulates rapidly. Combined with metabolic acidosis (which shifts K+ out of cells), dietary indiscretion, and certain medications, serum potassium can reach lethal levels quickly.</p>

<h4>ECG Progression of Hyperkalemia</h4>

<div class="diagram-container">
<svg viewBox="0 0 800 130" xmlns="http://www.w3.org/2000/svg" width="800" height="130" role="img" aria-label="ECG progression of hyperkalemia: mild peaked T waves, moderate flat P waves and prolonged PR, severe widened QRS, critical sine wave pattern leading to V-fib and cardiac arrest">
  <rect width="800" height="130" fill="#fafafa" rx="6"/>
  <!-- Stages -->
  <rect x="15" y="20" width="130" height="90" rx="6" fill="#fff9c4" stroke="#f9a825" stroke-width="1.5"/>
  <text x="80" y="42" text-anchor="middle" font-size="11" font-weight="bold" fill="#f57f17">Mild (5.5-6.0)</text>
  <text x="80" y="62" text-anchor="middle" font-size="10" fill="#333">Tall, peaked</text>
  <text x="80" y="76" text-anchor="middle" font-size="10" fill="#333">T waves</text>
  <text x="80" y="100" text-anchor="middle" font-size="9" fill="#666">(earliest sign)</text>

  <polygon points="150,65 163,55 163,75" fill="#424242"/>

  <rect x="170" y="20" width="130" height="90" rx="6" fill="#ffe0b2" stroke="#e65100" stroke-width="1.5"/>
  <text x="235" y="42" text-anchor="middle" font-size="11" font-weight="bold" fill="#e65100">Moderate (6.0-7.0)</text>
  <text x="235" y="62" text-anchor="middle" font-size="10" fill="#333">Flat P waves</text>
  <text x="235" y="76" text-anchor="middle" font-size="10" fill="#333">Prolonged PR</text>

  <polygon points="305,65 318,55 318,75" fill="#424242"/>

  <rect x="325" y="20" width="130" height="90" rx="6" fill="#ffccbc" stroke="#d84315" stroke-width="1.5"/>
  <text x="390" y="42" text-anchor="middle" font-size="11" font-weight="bold" fill="#d84315">Severe (7.0-8.0)</text>
  <text x="390" y="62" text-anchor="middle" font-size="10" fill="#333">Widened QRS</text>

  <polygon points="460,65 473,55 473,75" fill="#424242"/>

  <rect x="480" y="20" width="130" height="90" rx="6" fill="#ef9a9a" stroke="#c62828" stroke-width="1.5"/>
  <text x="545" y="42" text-anchor="middle" font-size="11" font-weight="bold" fill="#c62828">Critical (&gt;8.0)</text>
  <text x="545" y="62" text-anchor="middle" font-size="10" fill="#333">Sine wave</text>
  <text x="545" y="76" text-anchor="middle" font-size="10" fill="#333">pattern</text>

  <polygon points="615,65 628,55 628,75" fill="#424242"/>

  <rect x="635" y="20" width="145" height="90" rx="6" fill="#c62828" stroke="#b71c1c" stroke-width="2"/>
  <text x="707" y="50" text-anchor="middle" font-size="12" font-weight="bold" fill="#fff">V-fib /</text>
  <text x="707" y="68" text-anchor="middle" font-size="12" font-weight="bold" fill="#fff">CARDIAC</text>
  <text x="707" y="86" text-anchor="middle" font-size="12" font-weight="bold" fill="#fff">ARREST</text>
</svg>
</div>

<h4>Hyperkalemia Treatment</h4>
<table>
  <tr><th>Intervention</th><th>Mechanism</th><th>Onset</th><th>Notes</th></tr>
  <tr><td><strong>Calcium gluconate IV</strong></td><td>Stabilizes cardiac membrane</td><td>Minutes</td><td>Does NOT lower K+. Buys time. Cardioprotective</td></tr>
  <tr><td><strong>Regular insulin + IV glucose (D50)</strong></td><td>Drives K+ into cells</td><td>~30 min</td><td>Lasts several hours. Monitor for hypoglycemia</td></tr>
  <tr><td><strong>Sodium bicarbonate IV</strong></td><td>Alkalinizes serum, drives K+ into cells</td><td>~30 min</td><td>Use cautiously in fluid-overloaded patients</td></tr>
  <tr><td><strong>Nebulized albuterol</strong></td><td>Beta-2 stimulation drives K+ into cells</td><td>~30 min</td><td>Adjunct therapy</td></tr>
  <tr><td><strong>Kayexalate (sodium polystyrene sulfonate)</strong></td><td>Cation exchange resin removes K+ via GI tract</td><td>Hours</td><td>Oral or rectal. Can cause constipation/fecal impaction</td></tr>
  <tr><td><strong>Dialysis</strong></td><td>Definitive K+ removal</td><td>During session</td><td>Most effective long-term</td></tr>
</table>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  Calcium gluconate is always the FIRST intervention in hyperkalemic emergency&mdash;not because it lowers potassium (it doesn't), but because it stabilizes the myocardium against fatal dysrhythmias. You're buying time for the other treatments to work. Think of it as a cardiac shield.
</div>

<svg viewBox="0 0 760 720" style="max-width: 760px;" role="img" aria-label="Electrolyte imbalance quick reference grid covering sodium, potassium, calcium, and magnesium. For each electrolyte: normal range, hyperstate symptoms and treatment in red, and hypostate symptoms and treatment in blue. Includes ECG changes for potassium and calcium abnormalities.">
    <defs>
        <linearGradient id="elec-hyper" x1="0" y1="0" x2="1" y2="0">
            <stop offset="0%" stop-color="#ffcdd2"/>
            <stop offset="100%" stop-color="#ef9a9a"/>
        </linearGradient>
        <linearGradient id="elec-hypo" x1="0" y1="0" x2="1" y2="0">
            <stop offset="0%" stop-color="#bbdefb"/>
            <stop offset="100%" stop-color="#90caf9"/>
        </linearGradient>
    </defs>

    <!-- Title -->
    <text x="380" y="24" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">Electrolyte Imbalance Quick Reference</text>

    <!-- Column headers -->
    <rect x="10" y="38" width="100" height="28" rx="4" fill="#e8eaf6"/>
    <text x="60" y="57" text-anchor="middle" font-size="11" font-weight="bold" fill="#283593">Electrolyte</text>
    <rect x="115" y="38" width="315" height="28" rx="4" fill="url(#elec-hyper)"/>
    <text x="272" y="57" text-anchor="middle" font-size="11" font-weight="bold" fill="#c62828">&uarr; HYPER (Too High)</text>
    <rect x="435" y="38" width="315" height="28" rx="4" fill="url(#elec-hypo)"/>
    <text x="592" y="57" text-anchor="middle" font-size="11" font-weight="bold" fill="#1565c0">&darr; HYPO (Too Low)</text>

    <!-- ===== ROW 1: POTASSIUM ===== -->
    <rect x="10" y="72" width="100" height="155" rx="6" fill="#e8eaf6" stroke="#283593" stroke-width="1.5"/>
    <text x="60" y="105" text-anchor="middle" font-size="14" font-weight="bold" fill="#283593">K+</text>
    <text x="60" y="122" text-anchor="middle" font-size="10" fill="#283593">Potassium</text>
    <line x1="25" y1="132" x2="95" y2="132" stroke="#283593" stroke-width="0.5"/>
    <text x="60" y="148" text-anchor="middle" font-size="11" font-weight="bold" fill="#1a237e">3.5-5.0</text>
    <text x="60" y="162" text-anchor="middle" font-size="9" fill="#283593">mEq/L</text>
    <text x="60" y="185" text-anchor="middle" font-size="9" fill="#c62828" font-weight="bold">MOST</text>
    <text x="60" y="197" text-anchor="middle" font-size="9" fill="#c62828" font-weight="bold">DANGEROUS</text>
    <text x="60" y="218" text-anchor="middle" font-size="9" fill="#283593">80% excreted</text>
    <text x="60" y="228" text-anchor="middle" font-size="9" fill="#283593">by kidneys</text>

    <!-- Hyperkalemia -->
    <rect x="115" y="72" width="315" height="155" rx="6" fill="#fff5f5" stroke="#c62828" stroke-width="1"/>
    <text x="272" y="90" font-size="11" font-weight="bold" fill="#c62828" text-anchor="middle">Hyperkalemia (&gt;5.0)</text>
    <text x="125" y="108" font-size="10" fill="#4a5568">Muscle weakness, paresthesias</text>
    <text x="125" y="122" font-size="10" fill="#4a5568">Abdominal cramping, diarrhea</text>
    <text x="125" y="136" font-size="10" fill="#c62828" font-weight="bold">ECG: Peaked T &rarr; Flat P &rarr; Wide QRS</text>
    <text x="125" y="150" font-size="10" fill="#c62828" font-weight="bold">&rarr; Sine wave &rarr; V-fib/Arrest</text>
    <line x1="125" y1="158" x2="420" y2="158" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="125" y="174" font-size="10" fill="#2e7d32" font-weight="bold">Tx: Ca++ gluconate (cardiac shield)</text>
    <text x="125" y="188" font-size="10" fill="#2e7d32">Insulin+D50, bicarb, Kayexalate</text>
    <text x="125" y="202" font-size="10" fill="#2e7d32">Dialysis (definitive removal)</text>
    <text x="125" y="218" font-size="9" fill="#7B1FA2" font-style="italic">Causes: Renal failure, acidosis, K+-sparing diuretics</text>

    <!-- Hypokalemia -->
    <rect x="435" y="72" width="315" height="155" rx="6" fill="#f5f9ff" stroke="#1565c0" stroke-width="1"/>
    <text x="592" y="90" font-size="11" font-weight="bold" fill="#1565c0" text-anchor="middle">Hypokalemia (&lt;3.5)</text>
    <text x="445" y="108" font-size="10" fill="#4a5568">Muscle weakness, leg cramps</text>
    <text x="445" y="122" font-size="10" fill="#4a5568">Fatigue, decreased reflexes, ileus</text>
    <text x="445" y="136" font-size="10" fill="#1565c0" font-weight="bold">ECG: Flat T waves, U waves</text>
    <text x="445" y="150" font-size="10" fill="#1565c0" font-weight="bold">ST depression, arrhythmias</text>
    <line x1="445" y1="158" x2="740" y2="158" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="445" y="174" font-size="10" fill="#2e7d32" font-weight="bold">Tx: IV KCl (NEVER push; dilute)</text>
    <text x="445" y="188" font-size="10" fill="#2e7d32">Oral K+ supplements, K+-rich foods</text>
    <text x="445" y="202" font-size="10" fill="#c62828" font-weight="bold">&uarr; Digoxin toxicity risk!</text>
    <text x="445" y="218" font-size="9" fill="#7B1FA2" font-style="italic">Causes: Loop diuretics, vomiting, alkalosis</text>

    <!-- ===== ROW 2: SODIUM ===== -->
    <rect x="10" y="234" width="100" height="155" rx="6" fill="#e8eaf6" stroke="#283593" stroke-width="1.5"/>
    <text x="60" y="267" text-anchor="middle" font-size="14" font-weight="bold" fill="#283593">Na+</text>
    <text x="60" y="284" text-anchor="middle" font-size="10" fill="#283593">Sodium</text>
    <line x1="25" y1="294" x2="95" y2="294" stroke="#283593" stroke-width="0.5"/>
    <text x="60" y="310" text-anchor="middle" font-size="11" font-weight="bold" fill="#1a237e">136-145</text>
    <text x="60" y="324" text-anchor="middle" font-size="9" fill="#283593">mEq/L</text>
    <text x="60" y="350" text-anchor="middle" font-size="9" fill="#283593">Na+ goes</text>
    <text x="60" y="362" text-anchor="middle" font-size="9" fill="#283593">where water</text>
    <text x="60" y="374" text-anchor="middle" font-size="9" fill="#283593">follows</text>

    <!-- Hypernatremia -->
    <rect x="115" y="234" width="315" height="155" rx="6" fill="#fff5f5" stroke="#c62828" stroke-width="1"/>
    <text x="272" y="252" font-size="11" font-weight="bold" fill="#c62828" text-anchor="middle">Hypernatremia (&gt;145)</text>
    <text x="125" y="270" font-size="10" fill="#4a5568">Thirst (early), restlessness</text>
    <text x="125" y="284" font-size="10" fill="#4a5568">Dry mucous membranes, flushed skin</text>
    <text x="125" y="298" font-size="10" fill="#4a5568">Confusion, seizures (severe)</text>
    <text x="125" y="312" font-size="10" fill="#c62828" font-weight="bold">Cells shrink (water moves OUT)</text>
    <line x1="125" y1="320" x2="420" y2="320" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="125" y="336" font-size="10" fill="#2e7d32" font-weight="bold">Tx: Hypotonic fluids (0.45% NS)</text>
    <text x="125" y="350" font-size="10" fill="#2e7d32">Correct slowly (&le;12 mEq/L per 24h)</text>
    <text x="125" y="364" font-size="10" fill="#c62828">Too fast &rarr; cerebral edema!</text>
    <text x="125" y="380" font-size="9" fill="#7B1FA2" font-style="italic">Causes: Dehydration, diabetes insipidus, excess Na+</text>

    <!-- Hyponatremia -->
    <rect x="435" y="234" width="315" height="155" rx="6" fill="#f5f9ff" stroke="#1565c0" stroke-width="1"/>
    <text x="592" y="252" font-size="11" font-weight="bold" fill="#1565c0" text-anchor="middle">Hyponatremia (&lt;136)</text>
    <text x="445" y="270" font-size="10" fill="#4a5568">Headache, confusion, lethargy</text>
    <text x="445" y="284" font-size="10" fill="#4a5568">Nausea, muscle cramps</text>
    <text x="445" y="298" font-size="10" fill="#4a5568">Seizures, coma (severe)</text>
    <text x="445" y="312" font-size="10" fill="#1565c0" font-weight="bold">Cells swell (water moves IN)</text>
    <line x1="445" y1="320" x2="740" y2="320" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="445" y="336" font-size="10" fill="#2e7d32" font-weight="bold">Tx: Hypertonic (3% NS) if severe</text>
    <text x="445" y="350" font-size="10" fill="#2e7d32">Fluid restriction, Na+ replacement</text>
    <text x="445" y="364" font-size="10" fill="#c62828">Too fast &rarr; osmotic demyelination!</text>
    <text x="445" y="380" font-size="9" fill="#7B1FA2" font-style="italic">Causes: SIADH, diuretics, water intoxication</text>

    <!-- ===== ROW 3: CALCIUM ===== -->
    <rect x="10" y="396" width="100" height="155" rx="6" fill="#e8eaf6" stroke="#283593" stroke-width="1.5"/>
    <text x="60" y="429" text-anchor="middle" font-size="14" font-weight="bold" fill="#283593">Ca++</text>
    <text x="60" y="446" text-anchor="middle" font-size="10" fill="#283593">Calcium</text>
    <line x1="25" y1="456" x2="95" y2="456" stroke="#283593" stroke-width="0.5"/>
    <text x="60" y="472" text-anchor="middle" font-size="11" font-weight="bold" fill="#1a237e">8.6-10.2</text>
    <text x="60" y="486" text-anchor="middle" font-size="9" fill="#283593">mg/dL</text>
    <text x="60" y="510" text-anchor="middle" font-size="9" fill="#283593">Inverse to</text>
    <text x="60" y="522" text-anchor="middle" font-size="9" fill="#283593">phosphorus</text>
    <text x="60" y="540" text-anchor="middle" font-size="9" fill="#283593">Adjust for</text>
    <text x="60" y="550" text-anchor="middle" font-size="9" fill="#283593">albumin</text>

    <!-- Hypercalcemia -->
    <rect x="115" y="396" width="315" height="155" rx="6" fill="#fff5f5" stroke="#c62828" stroke-width="1"/>
    <text x="272" y="414" font-size="11" font-weight="bold" fill="#c62828" text-anchor="middle">Hypercalcemia (&gt;10.2)</text>
    <text x="125" y="432" font-size="10" fill="#4a5568">Lethargy, confusion, weakness</text>
    <text x="125" y="446" font-size="10" fill="#4a5568">Constipation, kidney stones</text>
    <text x="125" y="460" font-size="10" fill="#c62828" font-weight="bold">ECG: Shortened QT interval</text>
    <text x="125" y="474" font-size="10" fill="#4a5568">Decreased deep tendon reflexes</text>
    <line x1="125" y1="482" x2="420" y2="482" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="125" y="498" font-size="10" fill="#2e7d32" font-weight="bold">Tx: NS hydration, loop diuretics</text>
    <text x="125" y="512" font-size="10" fill="#2e7d32">Calcitonin, bisphosphonates</text>
    <text x="125" y="526" font-size="10" fill="#2e7d32">Dialysis (severe)</text>
    <text x="125" y="542" font-size="9" fill="#7B1FA2" font-style="italic">Causes: Malignancy, hyperparathyroidism</text>

    <!-- Hypocalcemia -->
    <rect x="435" y="396" width="315" height="155" rx="6" fill="#f5f9ff" stroke="#1565c0" stroke-width="1"/>
    <text x="592" y="414" font-size="11" font-weight="bold" fill="#1565c0" text-anchor="middle">Hypocalcemia (&lt;8.6)</text>
    <text x="445" y="432" font-size="10" fill="#4a5568">Numbness/tingling (perioral, fingers)</text>
    <text x="445" y="446" font-size="10" fill="#4a5568">Muscle spasms, tetany, seizures</text>
    <text x="445" y="460" font-size="10" fill="#1565c0" font-weight="bold">ECG: Prolonged QT interval</text>
    <text x="445" y="474" font-size="10" fill="#1565c0" font-weight="bold">+Trousseau's, +Chvostek's signs</text>
    <line x1="445" y1="482" x2="740" y2="482" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="445" y="498" font-size="10" fill="#2e7d32" font-weight="bold">Tx: IV calcium gluconate (slow)</text>
    <text x="445" y="512" font-size="10" fill="#2e7d32">Oral Ca++ &amp; Vitamin D supplements</text>
    <text x="445" y="526" font-size="10" fill="#2e7d32">Phosphate binders (if CKD)</text>
    <text x="445" y="542" font-size="9" fill="#7B1FA2" font-style="italic">Causes: CKD, hypoparathyroidism, low Vit D</text>

    <!-- ===== ROW 4: MAGNESIUM ===== -->
    <rect x="10" y="558" width="100" height="155" rx="6" fill="#e8eaf6" stroke="#283593" stroke-width="1.5"/>
    <text x="60" y="591" text-anchor="middle" font-size="14" font-weight="bold" fill="#283593">Mg++</text>
    <text x="60" y="608" text-anchor="middle" font-size="10" fill="#283593">Magnesium</text>
    <line x1="25" y1="618" x2="95" y2="618" stroke="#283593" stroke-width="0.5"/>
    <text x="60" y="634" text-anchor="middle" font-size="11" font-weight="bold" fill="#1a237e">1.5-2.5</text>
    <text x="60" y="648" text-anchor="middle" font-size="9" fill="#283593">mEq/L</text>
    <text x="60" y="672" text-anchor="middle" font-size="9" fill="#283593">Follows K+</text>
    <text x="60" y="684" text-anchor="middle" font-size="9" fill="#283593">(fix Mg first</text>
    <text x="60" y="696" text-anchor="middle" font-size="9" fill="#283593">to fix K+)</text>

    <!-- Hypermagnesemia -->
    <rect x="115" y="558" width="315" height="155" rx="6" fill="#fff5f5" stroke="#c62828" stroke-width="1"/>
    <text x="272" y="576" font-size="11" font-weight="bold" fill="#c62828" text-anchor="middle">Hypermagnesemia (&gt;2.5)</text>
    <text x="125" y="594" font-size="10" fill="#4a5568">Lethargy, drowsiness, flushing</text>
    <text x="125" y="608" font-size="10" fill="#4a5568">Decreased DTRs (early sign)</text>
    <text x="125" y="622" font-size="10" fill="#4a5568">Hypotension, bradycardia</text>
    <text x="125" y="636" font-size="10" fill="#c62828" font-weight="bold">Respiratory depression (severe)</text>
    <line x1="125" y1="644" x2="420" y2="644" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="125" y="660" font-size="10" fill="#2e7d32" font-weight="bold">Tx: IV calcium gluconate (antidote)</text>
    <text x="125" y="674" font-size="10" fill="#2e7d32">NS + loop diuretics, dialysis</text>
    <text x="125" y="688" font-size="10" fill="#2e7d32">Ventilatory support if needed</text>
    <text x="125" y="704" font-size="9" fill="#7B1FA2" font-style="italic">Causes: Renal failure, excess Mg (antacids, laxatives)</text>

    <!-- Hypomagnesemia -->
    <rect x="435" y="558" width="315" height="155" rx="6" fill="#f5f9ff" stroke="#1565c0" stroke-width="1"/>
    <text x="592" y="576" font-size="11" font-weight="bold" fill="#1565c0" text-anchor="middle">Hypomagnesemia (&lt;1.5)</text>
    <text x="445" y="594" font-size="10" fill="#4a5568">Tremors, hyperactive DTRs</text>
    <text x="445" y="608" font-size="10" fill="#4a5568">Seizures, confusion</text>
    <text x="445" y="622" font-size="10" fill="#4a5568">Cardiac arrhythmias (torsades)</text>
    <text x="445" y="636" font-size="10" fill="#1565c0" font-weight="bold">+Trousseau's, +Chvostek's (like Ca++)</text>
    <line x1="445" y1="644" x2="740" y2="644" stroke="#e0e0e0" stroke-width="0.5"/>
    <text x="445" y="660" font-size="10" fill="#2e7d32" font-weight="bold">Tx: IV magnesium sulfate (slow)</text>
    <text x="445" y="674" font-size="10" fill="#2e7d32">Oral Mg supplements</text>
    <text x="445" y="688" font-size="10" fill="#c62828" font-weight="bold">Must correct before K+ will correct!</text>
    <text x="445" y="704" font-size="9" fill="#7B1FA2" font-style="italic">Causes: Alcoholism, diuretics, malnutrition</text>
</svg>

<!-- ============================================================ -->
<!-- SECTION 5: RENAL REPLACEMENT THERAPY -->
<!-- ============================================================ -->
<h2 id="s5">5. Renal Replacement Therapy <span class="tag-heavy">HEAVY IN SLIDES</span></h2>

<p>When the kidneys can no longer sustain life, renal replacement therapy takes over. The three modalities&mdash;hemodialysis, peritoneal dialysis, and CRRT&mdash;use different mechanisms but share the same goal: remove toxic waste products, excess fluid, and restore electrolyte balance. None of them cure kidney disease. They are life support.</p>

<svg viewBox="0 0 740 600" style="max-width: 740px;" role="img" aria-label="Hemodialysis versus Peritoneal Dialysis comparison. Left side shows hemodialysis with AV fistula access, external dialyzer circuit, 3-4 times per week for 3-4 hours, rapid fluid removal. Right side shows peritoneal dialysis with abdominal catheter, dialysate dwelling in peritoneal cavity, daily exchanges or nightly cycler, gradual fluid removal. Each includes advantages, disadvantages, and complications.">
    <defs>
        <linearGradient id="hd-bg" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#e3f2fd"/>
            <stop offset="100%" stop-color="#bbdefb"/>
        </linearGradient>
        <linearGradient id="pd-bg" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#e8f5e9"/>
            <stop offset="100%" stop-color="#c8e6c9"/>
        </linearGradient>
    </defs>

    <!-- Title -->
    <text x="370" y="26" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">Hemodialysis vs. Peritoneal Dialysis</text>

    <!-- ===== LEFT: HEMODIALYSIS ===== -->
    <rect x="15" y="45" width="345" height="540" rx="10" fill="url(#hd-bg)" stroke="#1565c0" stroke-width="2"/>
    <rect x="15" y="45" width="345" height="36" rx="10" fill="#1565c0"/>
    <rect x="15" y="71" width="345" height="10" fill="#1565c0"/>
    <text x="187" y="69" text-anchor="middle" font-size="15" font-weight="bold" fill="white">HEMODIALYSIS</text>

    <!-- AV Fistula icon -->
    <circle cx="187" cy="120" r="30" fill="white" stroke="#1565c0" stroke-width="1.5"/>
    <!-- Arm with fistula -->
    <path d="M 170,108 L 170,132" stroke="#c62828" stroke-width="3" fill="none"/>
    <path d="M 204,108 L 204,132" stroke="#1565c0" stroke-width="3" fill="none"/>
    <path d="M 170,118 Q 187,125 204,118" stroke="#7B1FA2" stroke-width="2" fill="none"/>
    <text x="187" y="148" text-anchor="middle" font-size="9" fill="#1565c0" font-style="italic">AV Fistula</text>

    <!-- Key facts -->
    <rect x="30" y="160" width="315" height="28" rx="4" fill="white" stroke="#1565c0" stroke-width="1" opacity="0.8"/>
    <text x="187" y="179" text-anchor="middle" font-size="11" fill="#0d47a1" font-weight="bold">3-4x/week | 3-4 hours each</text>

    <rect x="30" y="196" width="315" height="28" rx="4" fill="white" stroke="#1565c0" stroke-width="1" opacity="0.8"/>
    <text x="187" y="215" text-anchor="middle" font-size="11" fill="#0d47a1" font-weight="bold">Rapid fluid removal (ultrafiltration)</text>

    <!-- How it works -->
    <text x="35" y="248" font-size="11" fill="#0d47a1" font-weight="bold">How It Works:</text>
    <text x="35" y="264" font-size="10" fill="#1a237e">Blood drawn from AV fistula/graft/catheter</text>
    <text x="35" y="278" font-size="10" fill="#1a237e">&rarr; Pumped through external dialyzer</text>
    <text x="35" y="292" font-size="10" fill="#1a237e">&rarr; Diffusion, osmosis, ultrafiltration</text>
    <text x="35" y="306" font-size="10" fill="#1a237e">&rarr; Cleaned blood returned to patient</text>

    <!-- Advantages -->
    <text x="35" y="332" font-size="11" fill="#2e7d32" font-weight="bold">Advantages:</text>
    <text x="35" y="348" font-size="10" fill="#1b5e20">&bull; Efficient toxin/fluid removal</text>
    <text x="35" y="362" font-size="10" fill="#1b5e20">&bull; Done at dialysis center (supervised)</text>
    <text x="35" y="376" font-size="10" fill="#1b5e20">&bull; 3 days off between sessions</text>

    <!-- Disadvantages -->
    <text x="35" y="400" font-size="11" fill="#c62828" font-weight="bold">Disadvantages:</text>
    <text x="35" y="416" font-size="10" fill="#b71c1c">&bull; Hemodynamic stress (rapid fluid shifts)</text>
    <text x="35" y="430" font-size="10" fill="#b71c1c">&bull; Vascular access required (fistula/graft)</text>
    <text x="35" y="444" font-size="10" fill="#b71c1c">&bull; Strict diet/fluid restrictions</text>

    <!-- Complications -->
    <text x="35" y="468" font-size="11" fill="#d97706" font-weight="bold">Complications:</text>
    <text x="35" y="484" font-size="10" fill="#e65100">&bull; Hypotension (most common)</text>
    <text x="35" y="498" font-size="10" fill="#e65100">&bull; Infection (access site)</text>
    <text x="35" y="512" font-size="10" fill="#e65100">&bull; Clotting of access</text>
    <text x="35" y="526" font-size="10" fill="#e65100">&bull; Disequilibrium syndrome</text>

    <!-- Nursing key -->
    <rect x="30" y="540" width="315" height="35" rx="4" fill="#fff3e0" stroke="#d97706" stroke-width="1"/>
    <text x="187" y="557" text-anchor="middle" font-size="10" fill="#e65100" font-weight="bold">NEVER take BP, draw blood, or start IV</text>
    <text x="187" y="571" text-anchor="middle" font-size="10" fill="#e65100" font-weight="bold">in the fistula arm! Feel for thrill/bruit.</text>

    <!-- ===== RIGHT: PERITONEAL DIALYSIS ===== -->
    <rect x="380" y="45" width="345" height="540" rx="10" fill="url(#pd-bg)" stroke="#2e7d32" stroke-width="2"/>
    <rect x="380" y="45" width="345" height="36" rx="10" fill="#2e7d32"/>
    <rect x="380" y="71" width="345" height="10" fill="#2e7d32"/>
    <text x="552" y="69" text-anchor="middle" font-size="15" font-weight="bold" fill="white">PERITONEAL DIALYSIS</text>

    <!-- PD catheter icon -->
    <circle cx="552" cy="120" r="30" fill="white" stroke="#2e7d32" stroke-width="1.5"/>
    <!-- Abdomen with catheter -->
    <ellipse cx="552" cy="122" rx="18" ry="14" fill="none" stroke="#2e7d32" stroke-width="1.5"/>
    <line x1="552" y1="136" x2="552" y2="148" stroke="#d97706" stroke-width="2.5"/>
    <text x="552" y="148" text-anchor="middle" font-size="9" fill="#2e7d32" font-style="italic">PD Catheter</text>

    <!-- Key facts -->
    <rect x="395" y="160" width="315" height="28" rx="4" fill="white" stroke="#2e7d32" stroke-width="1" opacity="0.8"/>
    <text x="552" y="179" text-anchor="middle" font-size="11" fill="#1b5e20" font-weight="bold">Daily (CAPD) or Nightly (CCPD)</text>

    <rect x="395" y="196" width="315" height="28" rx="4" fill="white" stroke="#2e7d32" stroke-width="1" opacity="0.8"/>
    <text x="552" y="215" text-anchor="middle" font-size="11" fill="#1b5e20" font-weight="bold">Gradual fluid removal (osmosis)</text>

    <!-- How it works -->
    <text x="400" y="248" font-size="11" fill="#1b5e20" font-weight="bold">How It Works:</text>
    <text x="400" y="264" font-size="10" fill="#1b5e20">Dialysate infused into peritoneal cavity</text>
    <text x="400" y="278" font-size="10" fill="#1b5e20">&rarr; Dwells for prescribed time</text>
    <text x="400" y="292" font-size="10" fill="#1b5e20">&rarr; Peritoneum acts as dialysis membrane</text>
    <text x="400" y="306" font-size="10" fill="#1b5e20">&rarr; Effluent drained, fresh dialysate instilled</text>

    <!-- Advantages -->
    <text x="400" y="332" font-size="11" fill="#2e7d32" font-weight="bold">Advantages:</text>
    <text x="400" y="348" font-size="10" fill="#1b5e20">&bull; Home-based (independence)</text>
    <text x="400" y="362" font-size="10" fill="#1b5e20">&bull; Gentler hemodynamic shifts</text>
    <text x="400" y="376" font-size="10" fill="#1b5e20">&bull; Preserves residual kidney function longer</text>

    <!-- Disadvantages -->
    <text x="400" y="400" font-size="11" fill="#c62828" font-weight="bold">Disadvantages:</text>
    <text x="400" y="416" font-size="10" fill="#b71c1c">&bull; Peritonitis risk (biggest concern)</text>
    <text x="400" y="430" font-size="10" fill="#b71c1c">&bull; Requires patient/caregiver training</text>
    <text x="400" y="444" font-size="10" fill="#b71c1c">&bull; Protein loss through peritoneum</text>

    <!-- Complications -->
    <text x="400" y="468" font-size="11" fill="#d97706" font-weight="bold">Complications:</text>
    <text x="400" y="484" font-size="10" fill="#e65100">&bull; Peritonitis (cloudy effluent = #1 sign)</text>
    <text x="400" y="498" font-size="10" fill="#e65100">&bull; Hyperglycemia (glucose in dialysate)</text>
    <text x="400" y="512" font-size="10" fill="#e65100">&bull; Exit site infection</text>
    <text x="400" y="526" font-size="10" fill="#e65100">&bull; Respiratory compromise (fluid in abdomen)</text>

    <!-- Nursing key -->
    <rect x="395" y="540" width="315" height="35" rx="4" fill="#fff3e0" stroke="#d97706" stroke-width="1"/>
    <text x="552" y="557" text-anchor="middle" font-size="10" fill="#e65100" font-weight="bold">Cloudy effluent = peritonitis until</text>
    <text x="552" y="571" text-anchor="middle" font-size="10" fill="#e65100" font-weight="bold">proven otherwise! Culture &amp; notify MD.</text>
</svg>

<h3 id="s5a">5.1 Hemodialysis <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<h4>Indications</h4>
<p>Hemodialysis is indicated when conservative management can no longer control the consequences of kidney failure: rising or dangerously high potassium, fluid overload or impending pulmonary edema, increasing metabolic acidosis, uremic symptoms (pericarditis, encephalopathy, neuropathy), and removal of certain medications or toxins.</p>

<h4>Principles of Hemodialysis</h4>
<p>Blood is pumped from the patient through an artificial kidney (dialyzer) and back to the patient. Three physical principles drive the process:</p>
<ul>
  <li><strong>Diffusion:</strong> Solutes (urea, creatinine, electrolytes, drugs) move from high concentration (blood) to low concentration (dialysate) across the semipermeable membrane</li>
  <li><strong>Osmosis:</strong> Water moves from low to high solute concentration</li>
  <li><strong>Ultrafiltration:</strong> Hydrostatic pressure pushes excess water across the membrane. Controlled by adjusting transmembrane pressure</li>
</ul>
<p>The dialyzer uses a hollow-fiber design: blood flows through thousands of thin capillary fibers while dialysate flows around them in the opposite direction (countercurrent flow), maximizing the concentration gradient and efficiency. A typical HD schedule is three times per week, 3&ndash;4 hours per session.</p>

<h4>Vascular Access <span class="tag-heavy">HEAVY IN SLIDES</span></h4>

<table>
  <tr><th>Access Type</th><th>Description</th><th>Maturation</th><th>Advantages</th><th>Disadvantages</th></tr>
  <tr><td><strong>AV Fistula (AVF)</strong></td><td>Surgical anastomosis of artery to vein (usually radial artery to cephalic vein)</td><td>3&ndash;6 months</td><td><strong>Preferred long-term access.</strong> Lowest infection and thrombosis risk. Longest patency</td><td>Long maturation time. Not all patients have suitable vessels</td></tr>
  <tr><td><strong>AV Graft (AVG)</strong></td><td>Synthetic tube connecting artery to vein</td><td>2&ndash;3 weeks</td><td>Usable sooner than AVF. Option when native vessels inadequate</td><td>Higher infection and thrombosis risk than AVF</td></tr>
  <tr><td><strong>HD Catheter</strong></td><td>Double-lumen catheter in subclavian, internal jugular, or femoral vein</td><td>Immediate</td><td>Available for acute or immediate use</td><td><strong>Highest infection risk.</strong> Should be temporary. Risk of stenosis</td></tr>
</table>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; Protecting the AV Fistula</div>
  <ul>
    <li><strong>NO blood pressure readings</strong> on the access arm</li>
    <li><strong>NO venipuncture or blood draws</strong> on the access arm</li>
    <li><strong>NO IV starts</strong> on the access arm</li>
    <li><strong>NO constrictive clothing or jewelry</strong> on the access arm</li>
    <li>Assess for <strong>thrill</strong> (palpable vibration) and <strong>bruit</strong> (audible whooshing)&mdash;presence confirms patency</li>
    <li>Teach patient: elevate arm, do not sleep on access arm, carry ID identifying the access</li>
    <li>Report signs of infection, decreased thrill/bruit, swelling, pain, or skin changes immediately</li>
  </ul>
</div>

<h4>Complications of Hemodialysis</h4>
<table>
  <tr><th>Complication</th><th>Cause</th><th>Nursing Action</th></tr>
  <tr><td><strong>Hypotension</strong> (most common)</td><td>Rapid fluid removal via ultrafiltration</td><td>Lower HOB, NS bolus, reduce ultrafiltration rate</td></tr>
  <tr><td><strong>Muscle cramps</strong></td><td>Rapid fluid/electrolyte shifts</td><td>NS bolus, adjust dialysis prescription</td></tr>
  <tr><td><strong>Nausea/Vomiting</strong></td><td>Hypotension, disequilibrium</td><td>Antiemetics, address underlying cause</td></tr>
  <tr><td><strong>Disequilibrium syndrome</strong></td><td>Rapid BUN reduction &rarr; cerebral edema</td><td>Slow dialysis rate, shorter sessions initially. Symptoms: headache, nausea, restlessness, seizures. More common with first treatment or very high BUN</td></tr>
  <tr><td><strong>Air embolism</strong></td><td>Air entering blood circuit</td><td>Clamp tubing, position patient on left side with head down</td></tr>
  <tr><td><strong>Access infection</strong></td><td>Bacterial contamination</td><td>Strict asepsis, monitor for redness/warmth/drainage, culture</td></tr>
</table>

<h3 id="s5b">5.2 Peritoneal Dialysis <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<p>Peritoneal dialysis uses the patient's own peritoneal membrane (surface area approximately 22,000 cm&sup2;) as a natural dialysis membrane. Sterile dialysate is infused through a surgically placed catheter into the peritoneal cavity, dwells for a prescribed time while diffusion and osmosis occur, and then drains by gravity.</p>

<h4>Types of Peritoneal Dialysis</h4>
<table>
  <tr><th>Type</th><th>Process</th><th>Lifestyle Impact</th></tr>
  <tr><td><strong>CAPD</strong> (Continuous Ambulatory)</td><td>4&ndash;5 manual exchanges per day. Infuse (10 min) &rarr; Dwell (4&ndash;8 hours) &rarr; Drain (20&ndash;30 min)</td><td>Patient-independent. No machine. Can do ADLs during dwell</td></tr>
  <tr><td><strong>CCPD</strong> (Continuous Cyclic)</td><td>Automated cycler performs 3&ndash;5 exchanges overnight while patient sleeps. May have long daytime dwell</td><td>Frees daytime hours. Machine-dependent at night</td></tr>
  <tr><td><strong>Acute Intermittent</strong></td><td>Hospital-based, manual exchanges for acute situations</td><td>Temporary</td></tr>
</table>

<p>Dialysate comes in different dextrose concentrations: 1.5%, 2.5%, and 4.25%. Higher concentrations pull more fluid across the membrane (greater ultrafiltration) but, used chronically, damage the peritoneal membrane over time. The physician orders the type of dialysate, number of exchanges per day, and dwell/drain times.</p>

<h4>Infection Control During PD <span class="tag-slides">SLIDES</span></h4>
<ul>
  <li>Strict hand hygiene before and during every exchange</li>
  <li>Wear mask and hair bonnet during exchanges</li>
  <li>No visitors during exchange; door closed</li>
  <li>Sterile cap placed on catheter during dwell periods</li>
  <li>Catheter exit site care: daily or 3&ndash;4 times weekly with soap and water during bathing. Do NOT submerge exit site in bathwater</li>
</ul>

<h4>Peritonitis &mdash; The Critical Complication <span class="tag-heavy">HEAVY IN SLIDES</span></h4>

<p>Peritonitis is the most common and most serious complication of peritoneal dialysis. It is caused by contamination during catheter connections/disconnections, exit site infection spreading internally, or translocation of bowel organisms.</p>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; Recognizing Peritonitis</div>
  The <strong>FIRST sign</strong> of peritonitis is <strong>CLOUDY DIALYSATE EFFLUENT</strong>. Normal effluent is clear and pale yellow. Cloudy effluent = peritonitis until proven otherwise. Other signs include diffuse abdominal pain with rebound tenderness, fever, nausea, general malaise, and in severe cases, hypotension and shock. <strong>Obtain a culture of the effluent FIRST, then start antibiotics.</strong> Treatment: intraperitoneal (IP) antibiotics added to dialysate plus systemic antibiotics. Continue dialysis during treatment.
</div>

<h4>Other PD Complications</h4>
<ul>
  <li>Catheter exit site and tunnel infections</li>
  <li>Protein loss in dialysate &rarr; hypoalbuminemia (malnutrition indicator)</li>
  <li>Hernias (from increased intra-abdominal pressure)</li>
  <li>Lower back pain, constipation</li>
  <li>Leakage at catheter site</li>
  <li>Bleeding</li>
</ul>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  If drainage is insufficient during PD, the first nursing action is to reposition the patient&mdash;roll them to the other side. Constipation is a common cause of poor drainage (bowel pressing on catheter), so maintaining regular bowel function is part of PD care that students often overlook.
</div>

<h3 id="s5c">5.3 Continuous Renal Replacement Therapy (CRRT) <span class="tag-slides">SLIDES</span></h3>

<p>CRRT is used in the ICU for hemodynamically unstable patients who cannot tolerate the rapid fluid and solute shifts of conventional hemodialysis. Instead of 3&ndash;4 hours, CRRT runs continuously over 24+ hours, removing fluid and toxins slowly and gently.</p>

<table>
  <tr><th>Type</th><th>Full Name</th><th>Primary Function</th></tr>
  <tr><td><strong>CVVH</strong></td><td>Continuous Venovenous Hemofiltration</td><td>Fluid removal (ultrafiltration)</td></tr>
  <tr><td><strong>CVVHD</strong></td><td>Continuous Venovenous Hemodialysis</td><td>Solute + fluid removal</td></tr>
  <tr><td><strong>CVVHDF</strong></td><td>Continuous Venovenous Hemodiafiltration</td><td>Combined filtration + dialysis</td></tr>
</table>
<p>CRRT requires continuous anticoagulation (heparin or citrate) and intensive nursing: hourly I&amp;O monitoring, frequent vital signs, anticoagulation management, and access site monitoring.</p>

<h3 id="s5d">5.4 Nursing the Hospitalized Dialysis Patient <span class="tag-heavy">HEAVY IN SLIDES</span></h3>

<p>When a patient who receives chronic dialysis is hospitalized for any reason, several critical nursing considerations apply on top of whatever brought them in.</p>

<h4>Protecting Vascular Access</h4>
<p>Assess the AV fistula or graft at every shift for thrill and bruit. Never use the access arm for BP, blood draws, or IV therapy. If the patient has an HD catheter, only a dialysis nurse or physician should access it. If used in an emergency, withdraw the catheter dwell volume before administering any medication or fluid.</p>

<h4>IV Therapy Precautions</h4>
<p>Patients on dialysis cannot excrete water. Any IV fluid must be given as <strong>slowly as possible</strong> to prevent volume overload and pulmonary edema. Use IV pumps for accuracy. Maintain meticulous I&amp;O records.</p>

<h4>Cardiovascular Monitoring &mdash; Pericarditis to Tamponade <span class="tag-slides">SLIDES</span></h4>
<p>Uremic toxin accumulation can damage the pericardium, triggering a dangerous progression:</p>

<div class="diagram-container">
<svg viewBox="0 0 800 170" xmlns="http://www.w3.org/2000/svg" width="800" height="170" role="img" aria-label="Pericarditis to cardiac tamponade progression: pericarditis with friction rub, pericardial effusion with muffled sounds, then cardiac tamponade emergency">
  <rect width="800" height="170" fill="#fafafa" rx="6"/>

  <rect x="15" y="25" width="220" height="120" rx="8" fill="#fff3e0" stroke="#e65100" stroke-width="2"/>
  <text x="125" y="48" text-anchor="middle" font-size="12" font-weight="bold" fill="#e65100">PERICARDITIS</text>
  <text x="125" y="68" text-anchor="middle" font-size="10" fill="#333">Substernal chest pain</text>
  <text x="125" y="83" text-anchor="middle" font-size="10" fill="#333">Low-grade fever</text>
  <text x="125" y="98" text-anchor="middle" font-size="10" fill="#333">Friction rub (present)</text>
  <text x="125" y="113" text-anchor="middle" font-size="10" fill="#e65100" font-weight="600">Pulsus paradoxus &gt;10 mmHg</text>
  <text x="125" y="133" text-anchor="middle" font-size="9" fill="#666">(BP drops &gt;10 on inspiration)</text>

  <polygon points="240,85 260,75 260,95" fill="#c62828"/>

  <rect x="270" y="25" width="220" height="120" rx="8" fill="#ffccbc" stroke="#d84315" stroke-width="2"/>
  <text x="380" y="48" text-anchor="middle" font-size="12" font-weight="bold" fill="#d84315">PERICARDIAL EFFUSION</text>
  <text x="380" y="68" text-anchor="middle" font-size="10" fill="#333">Friction rub DISAPPEARS</text>
  <text x="380" y="83" text-anchor="middle" font-size="10" fill="#333">Distant/muffled heart sounds</text>
  <text x="380" y="98" text-anchor="middle" font-size="10" fill="#333">Low-voltage ECG</text>
  <text x="380" y="113" text-anchor="middle" font-size="10" fill="#d84315" font-weight="600">Worsening pulsus paradoxus</text>

  <polygon points="495,85 515,75 515,95" fill="#c62828"/>

  <rect x="525" y="25" width="250" height="120" rx="8" fill="#c62828" stroke="#b71c1c" stroke-width="2"/>
  <text x="650" y="48" text-anchor="middle" font-size="12" font-weight="bold" fill="#fff">CARDIAC TAMPONADE</text>
  <text x="650" y="68" text-anchor="middle" font-size="10" fill="#fff">Narrowing pulse pressure</text>
  <text x="650" y="83" text-anchor="middle" font-size="10" fill="#fff">Muffled/inaudible heart sounds</text>
  <text x="650" y="98" text-anchor="middle" font-size="10" fill="#fff">Crushing chest pain, dyspnea</text>
  <text x="650" y="113" text-anchor="middle" font-size="10" fill="#fff" font-weight="bold">HYPOTENSION</text>
  <text x="650" y="133" text-anchor="middle" font-size="11" fill="#ffcdd2" font-weight="700">EMERGENCY: Pericardial window</text>
</svg>
</div>

<div class="callout memory">
  <div class="callout-title">Memory Anchor</div>
  <strong>Friction rub = pericarditis. Friction rub DISAPPEARS = effusion (fluid has filled the space and muffled the rubbing). Muffled heart sounds + hypotension + JVD = tamponade = EMERGENCY.</strong> The key clinical transition to watch for: a pericarditis patient whose friction rub suddenly goes away is getting <em>worse</em>, not better.
</div>

<h4>Blood Pressure Management</h4>
<p>Antihypertensive medications are typically <strong>held before dialysis</strong> and given <strong>after dialysis</strong>. The rationale: dialysis itself removes fluid, lowering blood pressure. If you combine fluid removal with a full dose of antihypertensive, the patient develops dangerous hypotension.</p>

<h4>Medication Considerations</h4>
<p>Many medications are cleared through dialysis, requiring dose adjustments or timing around treatments. All IV solutions and medications must be evaluated for their potassium and magnesium content. Avoid nephrotoxic drugs. Dialysis patients have increased infection risk (decreased phagocytic ability, low WBC function, impaired platelets) and increased bleeding risk.</p>

<h4>Psychological Support</h4>
<p>Chronic dialysis patients may consider discontinuing treatment. This must be taken seriously&mdash;not dismissed or treated as a crisis. The appropriate response is a psychiatric evaluation to rule out treatable depression, followed by counseling support. If depression is ruled out, the patient's informed decision should be respected as an advance directive.</p>

<!-- ============================================================ -->
<!-- SECTION 6: KIDNEY SURGERY & TRANSPLANTATION -->
<!-- ============================================================ -->
<h2 id="s6">6. Kidney Surgery &amp; Transplantation <span class="tag-slides">SLIDES</span></h2>

<h3 id="s6a">6.1 Kidney Surgery</h3>

<p>Kidney surgery may be performed to remove obstructions (tumors, calculi), insert drainage tubes, or remove a diseased kidney. Four surgical approaches are used: flank, lumbar, thoracoabdominal, and laparoscopic (least invasive, fastest recovery).</p>

<h4>Postoperative Priorities</h4>
<p>The kidney is a highly vascular organ. <strong>Hemorrhage and shock are the chief complications</strong> of kidney surgery. Fluid and blood component replacement is frequently needed in the immediate postoperative period.</p>

<table>
  <tr><th>Complication</th><th>Assessment Findings</th><th>Nursing Actions</th></tr>
  <tr><td><strong>Hemorrhage/Shock</strong></td><td>Fatigue, SOB, UO &lt;400 mL/24h, tachycardia. Late signs: cool skin, flat neck veins, altered LOC</td><td>Monitor VS frequently (initially hourly), assess incision and drains, report immediately</td></tr>
  <tr><td><strong>Paralytic ileus</strong></td><td>Abdominal distention, absent bowel sounds</td><td>NGT decompression. Oral fluids when flatus returns</td></tr>
  <tr><td><strong>Pneumonia</strong></td><td>Fever, increased HR/RR, adventitious breath sounds</td><td>Incentive spirometry, pain control, early ambulation, C&amp;DB exercises</td></tr>
  <tr><td><strong>Infection</strong></td><td>Redness, drainage, heat at incision; UTI from catheter</td><td>Strict asepsis, catheter care, remove invasive devices ASAP</td></tr>
  <tr><td><strong>Fluid imbalance</strong></td><td>Weight gain, pedal edema, UO &lt;400 mL/day, crackles (excess). Dehydration signs (deficit)</td><td>Daily weights, strict I&amp;O, infusion pump for all IV fluids. May need furosemide or dialysis</td></tr>
  <tr><td><strong>DVT</strong></td><td>Calf pain, swelling, redness, Homans sign (unreliable)</td><td>Anti-embolism stockings, leg exercises, early ambulation, anticoagulants as ordered</td></tr>
</table>

<h3 id="s6b">6.2 Kidney Transplantation <span class="tag-slides">SLIDES</span></h3>

<p>Kidney transplantation is the treatment of choice for selected patients with ESKD, but it is <strong>not a cure</strong>&mdash;the transplant will not function for the entire lifespan of most recipients. It is an elective procedure, not an emergency, and patients should be in the best possible condition beforehand.</p>

<h4>Donor Types</h4>
<p><strong>Living donor</strong> transplants (related or unrelated) have better long-term outcomes than deceased donor transplants. Paired exchange programs allow incompatible donor-recipient pairs to swap with other pairs to find compatible matches. <strong>Deceased donor</strong> kidneys may experience acute tubular necrosis and take 2&ndash;3 weeks to function. Living donor kidneys typically function immediately.</p>

<h4>Surgical Placement</h4>
<p>The transplanted kidney is placed in the iliac fossa (anterior to the iliac crest) for easier vascular access. The renal artery is sutured to the iliac artery, the renal vein to the iliac vein, and the ureter to the bladder. The patient's native kidneys are usually <strong>not removed</strong> (except for enlarged polycystic kidneys that risk rupture or infection).</p>

<h4>Contraindications to Transplant</h4>
<ul>
  <li>Recent malignancy</li>
  <li>Active or chronic infection (HIV, Hepatitis B/C)</li>
  <li>Severe irreversible extrarenal disease (inoperable cardiac disease, chronic lung disease, severe PVD)</li>
  <li>BMI &gt; 35 (Class II obesity)</li>
  <li>Active substance use disorder</li>
  <li>Inability to give informed consent</li>
  <li>Active psychiatric disease</li>
  <li>History of nonadherence to treatment regimens</li>
</ul>

<h4>Transplant Rejection <span class="tag-slides">SLIDES</span></h4>

<table>
  <tr><th>Type</th><th>Timing</th><th>Mechanism</th><th>Management</th></tr>
  <tr><td><strong>Hyperacute</strong></td><td>Within 24 hours</td><td>Antibody-mediated &rarr; glomerular capillary thrombosis &amp; necrosis</td><td><strong>Immediate removal</strong> of transplanted organ</td></tr>
  <tr><td><strong>Acute</strong></td><td>3&ndash;14 days (up to weeks)</td><td>T-cell mediated immune response</td><td>Increased immunosuppression. Signs: rising creatinine (may be ONLY sign on cyclosporine), fever, graft tenderness, malaise, oliguria (late)</td></tr>
  <tr><td><strong>Chronic</strong></td><td>Months to years</td><td>Progressive immune-mediated graft fibrosis</td><td>Optimize immunosuppression. May eventually require return to dialysis</td></tr>
</table>

<p>Detection methods include ultrasound (for hydronephrosis), percutaneous renal biopsy (<strong>most reliable</strong>), and nuclear medicine studies. Treatable rejection episodes during the first year are not uncommon. The 1-year graft survival rate is 90&ndash;95%.</p>

<h3 id="s6c">6.3 Immunosuppressant Medications <span class="tag-slides">SLIDES</span></h3>

<p>Immunosuppressive therapy is required for the <strong>entire lifetime</strong> of the transplant. The goal is to suppress the immune response enough to prevent rejection while preserving enough immune function to fight infections. It is a lifelong balancing act.</p>

<table>
  <tr><th>Agent</th><th>Class</th><th>Action</th><th>Critical Nursing Implications</th></tr>
  <tr><td><strong>Tacrolimus</strong></td><td>Calcineurin inhibitor</td><td>Inhibits helper T lymphocytes</td><td>Monitor for <strong>nephrotoxicity</strong>, hyperkalemia, neurotoxicity (tremors), HTN. Monitor drug levels</td></tr>
  <tr><td><strong>Cyclosporine</strong></td><td>Calcineurin inhibitor</td><td>Selective T-cell inhibition</td><td>Monitor <strong>nephrotoxicity</strong>, hirsutism, gingival hyperplasia. Give with food, same time daily. <strong>AVOID GRAPEFRUIT.</strong> Monitor drug levels</td></tr>
  <tr><td><strong>Sirolimus</strong></td><td>mTOR inhibitor</td><td>Inhibits helper T &amp; B lymphocytes</td><td>Swallow whole. Limit sun exposure. Give 4 hours AFTER cyclosporine</td></tr>
  <tr><td><strong>Mycophenolate mofetil</strong></td><td>Antiproliferative</td><td>Inhibits T- &amp; B-lymphocyte responses</td><td>GI upset&mdash;give with food. Do NOT crush capsules; avoid contact with powder (wash hands thoroughly if contact). Baseline CBC with differential</td></tr>
  <tr><td><strong>Belatacept</strong></td><td>Costimulation blocker</td><td>Inhibits T-lymphocyte proliferation</td><td><strong>IV only.</strong> Contraindicated in EBV seronegative. Monitor for PML (rare)</td></tr>
  <tr><td><strong>Everolimus</strong></td><td>mTOR inhibitor</td><td>Proliferation signal inhibitor</td><td>Monitor pulmonary status/cough. <strong>No live vaccines.</strong> Same time daily with food</td></tr>
  <tr><td><strong>Corticosteroids</strong></td><td>Anti-inflammatory</td><td>Suppress inflammatory &amp; immune response broadly</td><td>Long-term risks: Cushing syndrome, diabetes, osteoporosis, cataracts, GI bleeding, immunocompromise</td></tr>
</table>

<div class="callout warning">
  <div class="callout-title">Safety Alert &mdash; Grapefruit Interaction</div>
  Grapefruit and grapefruit juice interact with many immunosuppressant medications (particularly cyclosporine and tacrolimus) by inhibiting CYP3A4 enzyme activity, which raises drug levels to potentially toxic ranges. Transplant patients must be educated to <strong>avoid all grapefruit products</strong> for life.
</div>

<h4>Long-Term Immunosuppression Risks</h4>
<p>The medications themselves carry significant morbidity: nephrotoxicity (ironic but real&mdash;the drugs protecting the transplant can damage it), hypertension, hyperlipidemia, hirsutism, tremors, blood dyscrasias, cataracts, gingival hyperplasia, and increased cancer risk. Cardiovascular disease is the #1 cause of morbidity and mortality after transplantation. Patients require lifelong cancer screening beyond standard recommendations.</p>

<h3 id="s6d">6.4 Post-Transplant Nursing Management <span class="tag-slides">SLIDES</span></h3>

<h4>Assessing for Rejection</h4>
<p>The nurse monitors for: oliguria, edema, fever, increasing blood pressure, weight gain, and swelling or tenderness over the transplanted kidney. In patients receiving cyclosporine, the <strong>only sign of rejection may be an asymptomatic rise in serum creatinine</strong>&mdash;the classic symptoms may be masked. This is why lab monitoring is non-negotiable.</p>

<h4>Preventing Infection</h4>
<p>Immunosuppression makes the patient vulnerable to every infection:</p>
<ul>
  <li>Monitor WBC and platelet counts closely&mdash;immunosuppression depresses both</li>
  <li>Frequent urine cultures (high incidence of bacteriuria early and late post-transplant)</li>
  <li>Culture all wound drainage and catheter/drain tips on removal</li>
  <li>No fresh flowers in the transplant unit</li>
  <li>Strict hand hygiene by all who contact the patient</li>
  <li>Most infections occur in the first month (surgical complications, invasive devices, genitourinary focus)</li>
  <li>After 6 months with stable function: infectious risk decreases if no rejection episodes</li>
</ul>

<h4>Monitoring Urinary Function</h4>
<p>Output from the urinary catheter is measured <strong>every hour</strong>. IV fluids are given based on urine volume and serum electrolyte levels. If the kidney is from a deceased donor, ATN may cause anuria/oliguria/polyuria for 2&ndash;3 weeks, during which hemodialysis may be needed to maintain homeostasis.</p>

<h4>GI Complications</h4>
<p>Corticosteroid-induced GI ulceration and bleeding are managed prophylactically with H2 blockers (famotidine) or PPIs (omeprazole). Fungal colonization of the mouth and urinary bladder may occur from combined immunosuppression and antibiotic therapy&mdash;prophylactic oral antifungal rinses are standard.</p>

<h4>Patient Education for Discharge</h4>
<ul>
  <li>Lifelong immunosuppression&mdash;never stop medications without provider guidance</li>
  <li>Report immediately: decreased urine output, weight gain, malaise, fever, respiratory distress, tenderness over graft, changes in eating/drinking habits, blood pressure changes, anxiety, depression</li>
  <li>Inform ALL health care providers (including dentists) about the transplant and immunosuppressive regimen</li>
  <li>Avoid contact sports (risk of graft injury)</li>
  <li>Follow-up: initially 1&ndash;2 times per week, tapering over time. Lifelong lab monitoring</li>
  <li>Cancer screening: higher risk than general population due to immunosuppression</li>
  <li>Cardiovascular risk management: #1 cause of post-transplant morbidity and mortality</li>
</ul>

<div class="callout pearl">
  <div class="callout-title">Clinical Pearl</div>
  The living organ donor often experiences <strong>more pain</strong> than the transplant recipient and requires more analgesia. This is a common knowledge gap. Both donor and recipient need the same level of nursing care, including fluid/electrolyte/hemodynamic monitoring. The donor should have routine long-term follow-up for blood pressure monitoring, as one kidney is now handling the workload of two.
</div>

<!-- ============================================================ -->
<!-- INTEGRATION SECTION -->
<!-- ============================================================ -->
<h2 id="integration">Connecting It All: The Diabetes-to-Dialysis Continuum</h2>

<p>The material in this document is not two separate topics glued together. It is one continuous pathophysiologic story:</p>

<svg viewBox="0 0 700 820" style="max-width: 700px;" role="img" aria-label="Renin-Angiotensin-Aldosterone System cascade showing decreased renal perfusion triggering renin release from juxtaglomerular cells, converting angiotensinogen to angiotensin I, then ACE in the lungs converts it to angiotensin II, which causes vasoconstriction, aldosterone release for sodium and water retention, ADH release for water reabsorption, and thirst stimulation. Medication action sites shown: ACE inhibitors block conversion to angiotensin II, ARBs block angiotensin II receptors, and aldosterone antagonists block aldosterone effects.">
    <defs>
        <marker id="raas-arrow" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="7" markerHeight="7" orient="auto-start-reverse">
            <path d="M 0 0 L 10 5 L 0 10 Z" fill="#4a5568"/>
        </marker>
        <marker id="raas-arrow-red" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="7" markerHeight="7" orient="auto-start-reverse">
            <path d="M 0 0 L 10 5 L 0 10 Z" fill="#c62828"/>
        </marker>
        <linearGradient id="raas-trigger" x1="0" y1="0" x2="1" y2="0">
            <stop offset="0%" stop-color="#bbdefb"/>
            <stop offset="100%" stop-color="#90caf9"/>
        </linearGradient>
        <linearGradient id="raas-cascade" x1="0" y1="0" x2="1" y2="0">
            <stop offset="0%" stop-color="#c8e6c9"/>
            <stop offset="100%" stop-color="#a5d6a7"/>
        </linearGradient>
        <linearGradient id="raas-effect" x1="0" y1="0" x2="1" y2="0">
            <stop offset="0%" stop-color="#fff3e0"/>
            <stop offset="100%" stop-color="#ffe0b2"/>
        </linearGradient>
    </defs>

    <!-- Title -->
    <text x="350" y="26" text-anchor="middle" font-size="16" font-weight="bold" fill="#1a237e">Renin-Angiotensin-Aldosterone System (RAAS)</text>

    <!-- Box 1: Trigger -->
    <rect x="180" y="45" rx="8" ry="8" width="340" height="50" fill="url(#raas-trigger)" stroke="#1565c0" stroke-width="2"/>
    <text x="350" y="67" text-anchor="middle" font-size="13" font-weight="bold" fill="#0d47a1">&darr; Renal Perfusion</text>
    <text x="350" y="84" text-anchor="middle" font-size="10" fill="#1565c0">(Low BP, low blood volume, hemorrhage)</text>
    <line x1="350" y1="95" x2="350" y2="115" stroke="#4a5568" stroke-width="1.5" marker-end="url(#raas-arrow)"/>

    <!-- Box 2: Renin -->
    <rect x="180" y="117" rx="8" ry="8" width="340" height="50" fill="url(#raas-cascade)" stroke="#2e7d32" stroke-width="1.5"/>
    <text x="350" y="139" text-anchor="middle" font-size="13" font-weight="bold" fill="#1b5e20">Juxtaglomerular Cells Release RENIN</text>
    <text x="350" y="156" text-anchor="middle" font-size="10" fill="#2e7d32">(Kidney &mdash; afferent arteriole)</text>
    <line x1="350" y1="167" x2="350" y2="187" stroke="#4a5568" stroke-width="1.5" marker-end="url(#raas-arrow)"/>

    <!-- Box 3: Angiotensinogen  Angiotensin I -->
    <rect x="180" y="189" rx="8" ry="8" width="340" height="50" fill="url(#raas-cascade)" stroke="#2e7d32" stroke-width="1.5"/>
    <text x="350" y="211" text-anchor="middle" font-size="13" font-weight="bold" fill="#1b5e20">Angiotensinogen &rarr; Angiotensin I</text>
    <text x="350" y="228" text-anchor="middle" font-size="10" fill="#2e7d32">(Angiotensinogen produced by liver)</text>
    <line x1="350" y1="239" x2="350" y2="259" stroke="#4a5568" stroke-width="1.5" marker-end="url(#raas-arrow)"/>

    <!-- ACE Inhibitor block site -->
    <rect x="500" y="240" rx="6" ry="6" width="175" height="42" fill="#ffcdd2" stroke="#c62828" stroke-width="2"/>
    <text x="587" y="258" text-anchor="middle" font-size="11" font-weight="bold" fill="#c62828">ACE Inhibitors</text>
    <text x="587" y="274" text-anchor="middle" font-size="10" fill="#b71c1c">(-pril) BLOCK HERE</text>
    <line x1="500" y1="261" x2="460" y2="270" stroke="#c62828" stroke-width="2" stroke-dasharray="5,3" marker-end="url(#raas-arrow-red)"/>

    <!-- Box 4: ACE converts to Angiotensin II -->
    <rect x="180" y="261" rx="8" ry="8" width="340" height="50" fill="url(#raas-cascade)" stroke="#2e7d32" stroke-width="2"/>
    <text x="350" y="283" text-anchor="middle" font-size="13" font-weight="bold" fill="#1b5e20">ACE (lungs) &rarr; Angiotensin II</text>
    <text x="350" y="300" text-anchor="middle" font-size="10" fill="#2e7d32">(Angiotensin-Converting Enzyme)</text>
    <line x1="350" y1="311" x2="350" y2="335" stroke="#4a5568" stroke-width="1.5" marker-end="url(#raas-arrow)"/>

    <!-- ARB block site -->
    <rect x="500" y="310" rx="6" ry="6" width="175" height="42" fill="#ffcdd2" stroke="#c62828" stroke-width="2"/>
    <text x="587" y="328" text-anchor="middle" font-size="11" font-weight="bold" fill="#c62828">ARBs</text>
    <text x="587" y="344" text-anchor="middle" font-size="10" fill="#b71c1c">(-sartan) BLOCK HERE</text>
    <line x1="500" y1="331" x2="460" y2="340" stroke="#c62828" stroke-width="2" stroke-dasharray="5,3" marker-end="url(#raas-arrow-red)"/>

    <!-- Box 5: Angiotensin II Effects (hub) -->
    <rect x="155" y="337" rx="10" ry="10" width="390" height="48" fill="#e8eaf6" stroke="#283593" stroke-width="2"/>
    <text x="350" y="358" text-anchor="middle" font-size="14" font-weight="bold" fill="#1a237e">Angiotensin II Effects</text>
    <text x="350" y="376" text-anchor="middle" font-size="10" fill="#283593">(Most potent vasoconstrictor in the body)</text>

    <!-- Four branches from Angiotensin II -->
    <!-- Branch 1: Vasoconstriction (left) -->
    <line x1="220" y1="385" x2="120" y2="420" stroke="#d97706" stroke-width="1.5" marker-end="url(#raas-arrow)"/>
    <rect x="30" y="422" rx="8" ry="8" width="180" height="55" fill="url(#raas-effect)" stroke="#d97706" stroke-width="1.5"/>
    <text x="120" y="443" text-anchor="middle" font-size="12" font-weight="bold" fill="#e65100">Vasoconstriction</text>
    <text x="120" y="460" text-anchor="middle" font-size="10" fill="#bf360c">&rarr; &uarr; Blood Pressure</text>
    <text x="120" y="474" text-anchor="middle" font-size="10" fill="#bf360c">(immediate effect)</text>

    <!-- Branch 2: Aldosterone (center-left) -->
    <line x1="290" y1="385" x2="250" y2="420" stroke="#d97706" stroke-width="1.5" marker-end="url(#raas-arrow)"/>
    <rect x="160" y="500" rx="8" ry="8" width="195" height="65" fill="url(#raas-effect)" stroke="#d97706" stroke-width="1.5"/>
    <text x="257" y="520" text-anchor="middle" font-size="12" font-weight="bold" fill="#e65100">Aldosterone Release</text>
    <text x="257" y="536" text-anchor="middle" font-size="10" fill="#bf360c">(Adrenal cortex)</text>
    <text x="257" y="552" text-anchor="middle" font-size="10" fill="#bf360c">&rarr; &uarr; Na+ &amp; H&#8322;O retention</text>
    <line x1="250" y1="477" x2="250" y2="498" stroke="#d97706" stroke-width="1.2" marker-end="url(#raas-arrow)"/>

    <!-- Aldosterone antagonist block -->
    <rect x="25" y="510" rx="6" ry="6" width="125" height="42" fill="#ffcdd2" stroke="#c62828" stroke-width="2"/>
    <text x="87" y="528" text-anchor="middle" font-size="10" font-weight="bold" fill="#c62828">Aldosterone</text>
    <text x="87" y="543" text-anchor="middle" font-size="10" fill="#b71c1c">Antagonists BLOCK</text>
    <line x1="150" y1="531" x2="160" y2="535" stroke="#c62828" stroke-width="2" stroke-dasharray="5,3" marker-end="url(#raas-arrow-red)"/>

    <!-- Branch 3: ADH (center-right) -->
    <line x1="410" y1="385" x2="450" y2="420" stroke="#d97706" stroke-width="1.5" marker-end="url(#raas-arrow)"/>
    <rect x="370" y="500" rx="8" ry="8" width="180" height="65" fill="url(#raas-effect)" stroke="#d97706" stroke-width="1.5"/>
    <text x="460" y="520" text-anchor="middle" font-size="12" font-weight="bold" fill="#e65100">ADH Release</text>
    <text x="460" y="536" text-anchor="middle" font-size="10" fill="#bf360c">(Posterior pituitary)</text>
    <text x="460" y="552" text-anchor="middle" font-size="10" fill="#bf360c">&rarr; &uarr; H&#8322;O reabsorption</text>
    <line x1="450" y1="477" x2="450" y2="498" stroke="#d97706" stroke-width="1.2" marker-end="url(#raas-arrow)"/>

    <!-- Branch 4: Thirst (right) -->
    <line x1="480" y1="385" x2="580" y2="420" stroke="#d97706" stroke-width="1.5" marker-end="url(#raas-arrow)"/>
    <rect x="490" y="422" rx="8" ry="8" width="180" height="55" fill="url(#raas-effect)" stroke="#d97706" stroke-width="1.5"/>
    <text x="580" y="443" text-anchor="middle" font-size="12" font-weight="bold" fill="#e65100">Thirst Stimulation</text>
    <text x="580" y="460" text-anchor="middle" font-size="10" fill="#bf360c">(Hypothalamus)</text>
    <text x="580" y="474" text-anchor="middle" font-size="10" fill="#bf360c">&rarr; &uarr; Fluid intake</text>

    <!-- All arrows converge to result -->
    <line x1="120" y1="477" x2="280" y2="600" stroke="#4a5568" stroke-width="1" stroke-dasharray="3,3"/>
    <line x1="257" y1="565" x2="300" y2="600" stroke="#4a5568" stroke-width="1" stroke-dasharray="3,3"/>
    <line x1="460" y1="565" x2="400" y2="600" stroke="#4a5568" stroke-width="1" stroke-dasharray="3,3"/>
    <line x1="580" y1="477" x2="420" y2="600" stroke="#4a5568" stroke-width="1" stroke-dasharray="3,3"/>

    <!-- Result box -->
    <rect x="180" y="602" rx="10" ry="10" width="340" height="50" fill="#1565c0" stroke="#0d47a1" stroke-width="2"/>
    <text x="350" y="624" text-anchor="middle" font-size="14" font-weight="bold" fill="white">&uarr; Blood Pressure + &uarr; Blood Volume</text>
    <text x="350" y="642" text-anchor="middle" font-size="10" fill="#bbdefb">Goal: Restore perfusion to kidneys</text>

    <!-- Feedback loop -->
    <path d="M 520,627 C 600,627 640,500 640,300 C 640,150 600,80 520,70"
          fill="none" stroke="#7B1FA2" stroke-width="1.5" stroke-dasharray="6,3" marker-end="url(#raas-arrow)"/>
    <text x="655" y="300" font-size="10" fill="#7B1FA2" font-weight="bold" transform="rotate(-90 655 300)">Negative feedback loop</text>

    <!-- Medication summary box -->
    <rect x="100" y="680" rx="8" ry="8" width="500" height="125" fill="#fff5f5" stroke="#c62828" stroke-width="1.5"/>
    <text x="350" y="702" text-anchor="middle" font-size="13" font-weight="bold" fill="#c62828">Medication Action Sites</text>

    <rect x="120" y="712" width="12" height="12" rx="2" fill="#c62828"/>
    <text x="138" y="723" font-size="11" fill="#4a5568"><tspan font-weight="bold">ACE Inhibitors</tspan> (-pril: lisinopril, enalapril) &mdash; Block ACE, &darr; Ang II</text>

    <rect x="120" y="734" width="12" height="12" rx="2" fill="#c62828"/>
    <text x="138" y="745" font-size="11" fill="#4a5568"><tspan font-weight="bold">ARBs</tspan> (-sartan: losartan, valsartan) &mdash; Block Ang II receptors</text>

    <rect x="120" y="756" width="12" height="12" rx="2" fill="#c62828"/>
    <text x="138" y="767" font-size="11" fill="#4a5568"><tspan font-weight="bold">Aldosterone Antagonists</tspan> (spironolactone) &mdash; Block aldosterone</text>

    <text x="350" y="795" text-anchor="middle" font-size="10" fill="#c62828" font-style="italic">Side effects: ACEi &rarr; dry cough, hyperkalemia | ARBs &rarr; similar but no cough | Both &rarr; monitor K+ and renal function</text>
</svg>

<div class="diagram-container">
<svg viewBox="0 0 800 190" xmlns="http://www.w3.org/2000/svg" width="800" height="190" role="img" aria-label="Diabetes to kidney failure continuum: uncontrolled diabetes leads to nephropathy, progressive CKD, ESKD, and lifelong dialysis or transplant">
  <rect width="800" height="190" fill="#fafafa" rx="6"/>
  <text x="400" y="22" text-anchor="middle" font-size="14" font-weight="bold" fill="#1a237e">The Diabetes &#x2192; Kidney Failure Continuum</text>

  <rect x="15" y="40" width="140" height="60" rx="8" fill="#e8eaf6" stroke="#1a237e" stroke-width="2"/>
  <text x="85" y="65" text-anchor="middle" font-size="11" font-weight="bold" fill="#1a237e">Uncontrolled</text>
  <text x="85" y="82" text-anchor="middle" font-size="11" font-weight="bold" fill="#1a237e">Diabetes</text>

  <polygon points="160,70 175,60 175,80" fill="#1a237e"/>

  <rect x="182" y="40" width="130" height="60" rx="8" fill="#e8eaf6" stroke="#1a237e" stroke-width="1.5"/>
  <text x="247" y="60" text-anchor="middle" font-size="10" fill="#333">Microvascular</text>
  <text x="247" y="75" text-anchor="middle" font-size="10" fill="#333">damage</text>
  <text x="247" y="90" text-anchor="middle" font-size="10" fill="#1a237e" font-weight="600">Nephropathy</text>

  <polygon points="317,70 332,60 332,80" fill="#1a237e"/>

  <rect x="340" y="40" width="120" height="60" rx="8" fill="#fff3e0" stroke="#e65100" stroke-width="1.5"/>
  <text x="400" y="60" text-anchor="middle" font-size="10" fill="#333">Progressive</text>
  <text x="400" y="75" text-anchor="middle" font-size="10" fill="#e65100" font-weight="600">CKD</text>
  <text x="400" y="90" text-anchor="middle" font-size="10" fill="#333">(Stages 1&#x2192;5)</text>

  <polygon points="465,70 480,60 480,80" fill="#c62828"/>

  <rect x="488" y="40" width="110" height="60" rx="8" fill="#fde8e8" stroke="#c62828" stroke-width="1.5"/>
  <text x="543" y="65" text-anchor="middle" font-size="11" font-weight="bold" fill="#c62828">ESKD</text>
  <text x="543" y="82" text-anchor="middle" font-size="10" fill="#333">GFR &lt; 15</text>

  <polygon points="603,70 618,60 618,80" fill="#c62828"/>

  <rect x="625" y="35" width="155" height="70" rx="8" fill="#c62828" stroke="#b71c1c" stroke-width="2"/>
  <text x="702" y="58" text-anchor="middle" font-size="11" font-weight="bold" fill="#fff">Dialysis or</text>
  <text x="702" y="76" text-anchor="middle" font-size="11" font-weight="bold" fill="#fff">Transplant</text>
  <text x="702" y="95" text-anchor="middle" font-size="9" fill="#ffcdd2">(lifelong)</text>

  <!-- Bottom annotation -->
  <rect x="60" y="120" width="680" height="55" rx="6" fill="#e8f5e9" stroke="#2e7d32" stroke-width="1"/>
  <text x="400" y="140" text-anchor="middle" font-size="11" fill="#2e7d32" font-weight="bold">Prevention Points (Where Nurses Make the Biggest Impact)</text>
  <text x="400" y="158" text-anchor="middle" font-size="10" fill="#1b5e20">A1C &lt; 7% | BP control | ACE inhibitors for microalbuminuria | Avoid nephrotoxins | Patient education</text>
</svg>
</div>

<p>Diabetes is the #1 cause of ESKD. Hypertension is #2. Both are modifiable. The earliest detectable sign of diabetic nephropathy is microalbuminuria, and ACE inhibitors can slow progression at this stage. Every nursing intervention aimed at glycemic control, blood pressure management, and medication adherence is simultaneously protecting the kidneys. By the time a patient reaches dialysis or transplant, the opportunities for prevention are gone&mdash;but the nursing expertise required only intensifies.</p>

<div class="callout pearl">
  <div class="callout-title">The Big Picture</div>
  When you're teaching a newly diagnosed diabetic patient about A1C goals and foot care, you're not just managing diabetes. You're potentially preventing a future life on dialysis. When you're protecting an AV fistula from a well-meaning phlebotomist, you're protecting that patient's literal lifeline. Every piece of this document connects to every other piece. The better you understand those connections, the better you'll think clinically&mdash;and the better your patients will do.
</div>

</main>
</div>

<script>
document.addEventListener('DOMContentLoaded', function() {
    var sections = document.querySelectorAll('h2[id], h3[id]');
    var navLinks = document.querySelectorAll('.toc a');

    function updateActiveLink() {
        var current = '';
        var scrollPos = window.scrollY + 120;
        for (var i = 0; i < sections.length; i++) {
            if (scrollPos >= sections[i].offsetTop) {
                current = sections[i].getAttribute('id');
            }
        }
        for (var j = 0; j < navLinks.length; j++) {
            var link = navLinks[j];
            if (link.getAttribute('href') === '#' + current) {
                link.classList.add('active');
                link.setAttribute('aria-current', 'true');
            } else {
                link.classList.remove('active');
                link.removeAttribute('aria-current');
            }
        }
    }

    var scrollTimer;
    window.addEventListener('scroll', function() {
        if (scrollTimer) cancelAnimationFrame(scrollTimer);
        scrollTimer = requestAnimationFrame(updateActiveLink);
    });
    updateActiveLink();
});
</script>
</body>
</html>